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Abstract 
I conducted a cost-effectiveness analysis of combination cetuximbab or panitumumab plus 
FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (MCRC) from 
the perspective of the Ontario healthcare payer. I developed a Markov decision analytical 
model to simulate the lifetime costs and benefits of each treatment option. The model was 
parameterized using data collected from administrative databases in the province of Ontario 
and from published clinical trials. In the base case scenario, treatment consisting of 
bevacizumab plus FOLFIRI was found to dominate other treatment options. The ICER 
values were found to be sensitive to the efficacy of first-line treatment, cost of bevacizumab 
and cetuximab, and health utility values. In conclusion the use of bevacizumab plus 
FOLFIRI, the current standard of care, is the most cost-effective first-line treatment option 
for patients with metastatic colorectal cancer in Ontario..   
 
 
Keywords 
Cost-Effectiveness, Metastatic Colorectal Cancer, Cetuximab, Bevacizumab, Panitumumab, 
Ontario, Markov Model. 
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Chapter 1  
1 Introduction 
 Colorectal cancer is the third most common cancer in males and second most common 
cancer in females, with over 1.2 million new cases and 608,700 deaths estimated to have 
occurred  worldwide in 2008 1.  In Canada, colorectal cancer is the second most common 
cause of cancer deaths, with an estimated 22,000 new cases were diagnosed in 2011, of 
which 8,900 of those cases being fatal 2. Of patients are diagnosed with colorectal cancer, 
approximately 15-25% will present with metastatic disease, and a further 40-50% will 
develop metastases in the course of their disease 3. The majority of the cases of death in 
colorectal cancer patients are due to the formation of secondary neoplasms outside of the 
colon or rectum 4.  In the past, most cases of metastatic colorectal cancer (MCRC) have 
been incurable and only palliative treatment options were available. However, in the past 
decade, treatments for patients with MCRC have been subject to a number of 
advancements in the treatment of MCRC such as the introduction of new 
chemotherapeutic agents like oxaliplatin, and the development of targeted monoclonal 
antibodies such as  bevacizumab (Avastin®), cetuximab (Erbitux®), and panitumumab 
(Vectibix®).  
 In particular, two fluorouracil containing chemotherapy regimens, FOLFOX which is 
comprised of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, and FOLFIRI which 
is comprised of irinotecan plus 5-FU and leucovorin, have been widely accepted as the 
primary first-line treatments for patients with MCRC. Both of these chemotherapy 
regimens have been found to be equally as efficacious in terms of patients’ overall 
response rate, time to progression, and overall survival 5, 6. The two chemotherapy 
regimens differ in their toxicity profiles; patients taking FOLFOX experience 
neurotoxicity, while patients taking FOLFIRI experience gastrointestinal side effects 5, 6. 
Unfortunately, the use of these chemotherapy regimens alone generally leads to an 
overall survival of less than 20 months 7, 8. Thus, more effective treatments for patients 
with metastatic disease have been sought after. 
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Bevacizumab (Avastin®) is a humanized monoclonal antibody that targets vascular 
endothelial growth factor A (VEGF-A) a key mediator in the angiogenesis of cancer 
cells9  and was the first monocolonal antibody to be approved for use in the treatment of 
colorectal cancer by Health Canada 10.  Randomized clinical trials (RCT) investigating 
combination therapy with either FOLFIRI or FOLFOX plus bevacizumab demonstrated 
an increase in patients’ overall response rate (ORR), overall survival (OS), and 
progression-free survival (PFS)  when compared to those chemotherapy regimens alone 
in both first-line 7, 11 and second-line 12 settings. The combination of bevacizumab with 
FOLFIRI or FOLFOX was also shown to be both safe and efficacious when used in 
routine clinical practice settings in two large observational studies both showing an 
increase in overall survival of these patients of greater than 20 months 13, 14. The results of 
these studies led to approval of the use of bevacizumab along with either FOLFIRI or 
FOLFOX chemotherapy regimens for use in first-line treatment for patients with MCRC 
by Health Canada in 2005 10, 15. 
After the introduction of bevacizumab, two other monoclonal antibodies, cetuximab and 
panitumumab, were introduced as potential treatment options for patients with metastatic 
colorectal cancer (MCRC). Both cetuximab (Erbitux®) and panitumumab (Vectibix®) 
are immunoglobulin G monoclonal antibodies that target the epidermal growth factor 
receptor (EGFR).  The EGFR is a clinically validated anticancer molecular target which 
is highly expressed in the majority of colorectal cancers 16, 17. Cetuximab is a chimeric 
(partially mouse and partially human) immunoglobulin which binds to EGFR with high 
affinity, competitively inhibiting EGFR downstream signaling, leading to cell 
cytotoxicity 18, 19.  Panitumumab is a fully human immunoglobulin G2 antibody that also 
binds the EGFR receptor with high affinity but whose binding prevents cancer cells TK 
autophosphorylation process, cell growth and metastasis 20.   
Although EGFR receptors are highly expressed in colorectal cancer cells, it is the KRAS 
gene that plays an important role in determining whether anti-EGFR monoclonal 
antibody treatment is suitable for these patients 21-24. Mutated KRAS genes are found in 
approximately 30-40% of patients with MCRC and KRAS mutation status acts as a 
predictive biomarker of resistance to treatment with both cetuximab and panitumumab 22, 
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24-27
.  KRAS is a signaling protein that works to activate a number of downstream protein 
targets which play an important role in cellular proliferation. The KRAS gene thus plays 
an important role in preventing further metastases while leading to cell death in those 
metastatic sites already present 24. Genetic testing of the KRAS gene for patients with 
metastatic colorectal cancers is needed before patients can begin treatment with either 
cetuximab or panitumumab as both therapies are only indicated for patients having wild 
type KRAS 28, 29.  Clinical trials examining for cetuximab and panitumumab as 
monotherapies as well as their use in combination with fluorouracil containing 
chemotherapy regimens have shown that patients with mutated KRAS have worse 
outcomes than those patients with wild-type KRAS 13, 30-33. Based on this observation, 
Health Canada has indicated cetuximab monotherapy for use in second or third-line 
treatment, or in combination with irinotecan as a third-line treatment, and panitumumab 
monotherapy as a third-line treatment for MCRC patients determined to have wild-type 
KRAS 28. 
Given the positive results of the addition of bevacizumab to fluorouracil containing 
chemotherapy regimens as a first-line treatment for patients, different researchers have 
investigated whether the addition of cetuximab or panitumumab to these regimens in 
first-line settings in patients with wild type KRAS would be promising. Indeed, these 
aforementioned studies, the researchers have found statistically significant increases in 
progression free survival (PFS) as well as non-significant a trend toward improved in 
overall response rate (ORR) and overall survival (OS) in combination therapy when 
compared to the chemotherapy regimens alone for patients with wild type KRAS 13, 16, 20, 
23, 30, 34-41
 . 
This project aims to evaluate the cost-effectiveness of the use of combination cetuximab 
or panitumumab plus FOLFIRI chemotherapy compared to the current clinical practice of 
the use of combination bevacizumab plus FOLFIRI as first-line treatment for KRAS 
wild-type MCRC patients from the perspective of the Ontario healthcare payer. In this 
analysis, clinical outcome data were obtained from both patient level data in the province 
of Ontario as well as from phase III and IV RCTs which have investigated the addition of 
cetuximab, panitumumab, and bevacizumab to either FOLFOX or FOLFIRI 
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chemotherapy. The cost-effectiveness of each treatment regimen will be determined 
through the development of a decision analytic model consisting of Markov models 
capturing the full disease course for patients receiving either of the possible first-line 
treatment strategies. This information will assist decision makers to decide whether 
cetuximab or panitumumab should be adopted as first-line treatment options for this 
specific patient population.   
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Chapter 2  
2 Literature Review 
2.1 Metastatic Colorectal Cancer 
Colorectal cancer develops as a consequence of the progressive accumulation of genetic 
and epigenetic changes within colonic epithelial cells which drive them to evolve to 
colon adenocarcinoma cells 42. The multi-stage process in which these changes occur is 
believed to occur over a 10-15 year period in which the colonic epithelial cells pick up 
biological characteristics, often involving the activation of proto-oncogenes and the 
deactivation of tumor suppressor genes which, in turn, lead to the malignant phenotype 42. 
The acquisition of these biological characteristics occurs through increased cellular 
genomic instability. Genomic instability occurs through a loss of the cell’s DNA fidelity 
due to errors in DNA sequencing and repair mechanisms which allow the genetic and 
epigenetic changes to accumulate over time 42-44. The mutations which drive the 
transformation from colonic epithelial cells to adenocarcioma cells provide a growth 
advantage which allows for adenocarcinoma cells’ clonal expansion, eventually leading 
to the development of adenocarcinomic colonic polyps 4, 42.  
Metastatic disease occurs when an adenocarcinoma cell(s) break off from the primary 
colonic tumors, travel to a secondary site, and proliferate into a secondary tumor. In order 
for a cancer to metastasize to a secondary site a number of sequential steps must 
successfully occur. To become a metastases cell(s) must first detach from the primary 
tumor and intravasate into the tumors blood or lymphatic vessels where it will travel 
through the individuals circulation system to reach secondary tumor sites 4. If the cancer 
cell is not destroyed in the circulatory system and is able to reach a secondary site it must 
then initiate the process of forming a secondary tumor. The secondary site which the 
circulating cell has travelled to must have a microenvironment which is permissive for 
the incoming tumor cell to extravasate into, grow, and form metastases 4. Due to different 
microenvironments being present in different organs, specific cancer cell types have 
organ preferences for which they tend to form metastases. In the case of colorectal 
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cancer, secondary tumors most often tend to develop in the liver and the lungs 4.  Once 
cells enter these sites their growth is regulated by cell-cell interactions with the cells 
present in their new environment 4. Many cells will die via apoptosis in their new 
environments; however those cells which can develop anti-apoptotic mechanisms and 
initiate vascularization will gain the capability to colonize 4. The metastatic process is not 
an easy one, as there are multiple obstacles a cell must pass in order for it to reach these 
secondary sites. Solitary cancer cells are very prone to death when in the circulation 
either through immune system mediated apoptosis or destruction via mechanical stresses 
4, 42
. It has been seen in animal studies that only 0.01% of circulating cancer cells 
eventually become secondary metastases 4. 
  
2.1.1 FOLFOX and FOLFIRI Chemotherapy Regimens 
Chemotherapy has been the primary approach for the treatment of metastatic colorectal 
cancer for over 40 years, with the fluoropyrimidine 5-fluororuracil (5-FU) being the 
constant of the initial chemotherapy regimens designed to target MCRC 45. The use of 5-
FU as a monotherapy was initially proven to be mildly effective, with overall response 
rates of 10-15% and median overall survival (OS) of only 6-8 months45. The lack of 
efficacy of 5-FU monotherapy fuelled the search for more effective strategies for the 
treatment of MCRC. Over the last 20 years, significant advances have been made leading 
to an increase in median OS to 18-24+ months in recent years 6, 15, 20, 46-49. These 
advancements are due to the development of chemotherapy drugs irinotecan, a 
topoisomerase I inhibitor, and oxaliplatin a third-generation platinum analog, as well as 
the development of the targeted monoclonal antibodies bevacizumab, cetuximab and 
panitumumab. 
 Conventional first-line treatment for patients with newly diagnosed, previously untreated 
MCRC is composed of a combination of chemotherapy drugs and certain targeted agents 
that either enhance the effectiveness of chemotherapy regimens, or have anti-cancer 
properties 45, 50. Two chemotherapy regimens, FOLFIRI and FOLFOX have become the 
standard chemotherapy treatments for patients with MCRC 51. Both regimens are 
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comprised of 5-FU and leucovorin. Leucovorin is a bio-modulating agent which enhances 
5-FU’s activity 45. FOLFOX involves the addition of oxaliplatin to 5-FU and leucovorin. 
Oxaliplatin is a platinum based compound that acts as a cytotoxic agent by forming both 
intrastrand and interstrand DNA crosslinks in cellular DNA 45.  The typical FOLFIRI 
regimen involves the addition of irinotecan, a topoisomerase I inhibitor which forms a 
stable complex with cellular DNA and topoisomerase I, an enzyme involved in the 
unwinding of DNA in the DNA replication process 45. Both of these treatment options 
lead to the prevention of cellular DNA replication and eventually resulting in the death of 
cancer cells 45.  
Both FOLFOX and FOLFIRI regimens are administered intravenously on a 14 day cycle. 
Although multiple variations of the FOLFOX and FOLFIRI regimens are cited in the 
literature, the most commonly used versions in Ontario are as follows: 
Modified FOLFOX6: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2, followed by bolus 
FU 400 mg/m2, followed by 46-hour infusion of FU 2400 mg/m2. 
FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2, followed by bolus FU 400 
mg/m2, followed by 46-hour infusion of FU 2400 mg/m2 50. 
Tournigand et al, conducted a randomized, multicentre, open-label, phase III clinical trial 
which compared a direct comparison of the FOLFIRI and FOLFOX chemotherapy 
regimens in both first and second-line settings for patients with metastatic colorectal 
cancer 5. The investigators randomized patients to either FOLFOX6 or FOLFIRI as initial 
treatment, and then switched patients to the other regimen upon disease progression. 
FOLFOX and FOLFIRI were found be equally as efficacious, having almost identical 
overall response rates (ORR) (56% and 54%), median OS (20.4 months vs 21.5 months),  
and 2 year survival (45% and 41%) with FOLFIRI having a longer, but statistically 
insignificant, median time to progression (TTP) in the first-line setting 5. Both regimens 
were equally well tolerated  by patients; however, the type of adverse events patients 
experienced were different as with patients taking FOLFOX6 experienced neurotoxicity 
while patients given FOLFIRI experiencing gastrointestinal side effects 5. Equivalency of 
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the two regimens in terms of TTP, duration of response, and OS were also seen in 
comparison of FOLFOX4 and FOLFIRI by Colucci et al 6. 
One difference between the FOLFOX and FOLFIRI chemotherapy regimens is that 
FOLFOX has been shown to result in higher rates of surgical resection of liver metastases 
than FOLFIRI.  In the Tournigand study, 21 of the 111 patients who received FOLFOX6 
were able to undergo R0 surgical liver resections, with 62% of them having complete 
resections of their liver metastases. This was significant as only 8 of the 109 patients who 
received FOLFIRI underwent R0 surgical resection, with only 6% having complete 
resection 5. This difference in resection rate has led to FOLFOX being more commonly 
administered as the first-line chemotherapy than FOLFIRI in the United States 51. Hess et 
al found in a review of 304,654 metastatic colorectal patients from 19 states in the United 
States between 2004 to 2008 that FOLFIRI was administered as a first line treatment to 
3.1% of patients while FOLFOX was  administered to 40.5%, 14.3% receiving FOLFOX 
alone and 26.2% receiving combination therapy consisting of FOLFOX and bevacizumab 
51
. By contrast, FOLFIRI is more commonly used than FOLFOX in the standard clinical 
practice in Ontario, mainly due to funding issues, as oxaliplatin is more expensive than 
irinotecan, making the FOLFOX regimen much more expensive than FOLFIRI 52, 53. 
 
2.1.2 Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-
Vascular Growth Endothelial Factor (VEGF) Therapies 
2.1.2.1 The EGFR and VEGF 
The Epidermal Growth Factor Receptor (EGFR) which also goes by the name the HER-1 
or c-erbB1 receptor is a trans-membrane glycoprotein that is a member of the erbB1 
family of tyrosine kinase receptors 54. The EGFR is a 170kDa glycoprotein that consists 
of an extracellular receptor domain, a trans-membrane region, and an intracellular 
domain that has tyrosine kinase activity 54. The EGFR is a clinically validated anticancer 
molecular target which is highly expressed in the majority of colorectal cancers 17. The 
function of the EGFR is to determine the behavior of epithelial cells, and its activation 
plays an important role in the behavior or tumors of epithelial cell origin such as MCRC 
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54, 55
. The EGFR binds a number of substrate ligands such as epidermal growth factors 
(EGF), heparin-binding EGF, transforming growth factor α, amphiregulin, and 
betacelulin 55.  The binding of these ligands to the EGFR leads to autophorylation of the 
receptor, which initiates a number of signal transduction pathways involved in cellular 
proliferation, differentiation, angiogenesis, the inhibition of apoptosis, cellular motility, 
cellular adhesion, and metastasis, thus making the EGFR and important mediator in the 
transformation of normal cells to malignant ones 25, 54, 56-59.  
EGFR over-expression has been characterized in breast, head-and-neck, non-small cell 
lung, renal, ovarian and colon cancers 54. EGFR over-expression intensifies signaling 
through its downstream pathways and results in cells that have more aggressive growth 
and invasiveness characteristics 57. EGFR expression has been associated with poorer 
patient prognosis and decreased survival as well as resistance to both chemotherapy and 
radiotherapy treatments 54. Due to the role EGFR expression plays in the development 
and maintenance of cancer cells, it has become an important molecular target for cancer 
therapies. Anti-EGFR monoclonal antibodies such as cetuximab and panitumumab 
function by targeting the extracellular domains of the EGFR in cells over-expressing the 
receptor while not affecting normal cells 37. Binding of these agents to the EGFR 
prevents receptor autophosphorylation and therefore prevents the activation of the 
downstream signal pathways 54. 
Activation of the EGFR has been found to stimulate Vascular Endothelial Growth Factor 
(VEGF), another molecular target for which monoclonal antibody therapy has been 
developed for the treatment of patients with MCRC. VEGF is a family comprised of 
seven members VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-F, and P1GF, which are 
soluble diffusible glycoproteins all of which have a common VEGF homology domain 60. 
Bevacizumab which is used in the treatment of patients with MCRC, specifically targets 
VEGF-A, a 32-43kDa protein which is released by cancer cells, hypoxic cells, as well as 
activated platelets and leukocytes, which play an important role in the angiogenic and 
neovascularisation processes 60, 61. VEGF-A isoform binds to two VEGF tyrosine kinase 
receptors, the VEGFR1 and VEGFR2, both of which are downstream receptor proteins 
who share a similar structure 60, 62. Binding of VGEF-A to either of these receptors results 
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in the activation of downstream signaling pathways which lead to endothelial cell 
proliferation and migration 60, 63. This proliferation and migration results in the formation 
of new tubular structures which mediate the development of new blood vessels from pre-
existing ones, providing cancer cells with oxygen and nutrients which promote tumor 
growth 60, 63. Due to the strong relationship between VEGF and angiogensis, VEGF 
serum levels have often been used as a surrogate biomarker for angiogenic activity in 
cancer patients 61. 
 
2.1.2.2 Bevacizumab and its Use with FOLFOX/FOLFIRI in First-
Line Treatment 
The development of bevacizumab (Avastin®) introduced a new, more targeted approach 
to treating MCRC. Bevacizumab is a humanized monoclonal antibody that binds and 
inhibits the action of all isoforms of the VEGF-A, a key mediator in the angiogenic 
process 7. Angiogenesis plays a vital role in driving tumor progression through the 
formation of new and aberrant blood vessels 48. In addition to preventing angiogenesis, 
bevacizumab prevents tumor growth through the normalization of tumor vasculature and 
the reduction of circulating endothelial and progenitor cancer cells 47, 48. Bevacizumab 
has also found to be associated with improved delivery of chemotherapy to cancerous 
cells by reducing interstitial pressure within tumors, and its use was approved for use 
along with fluouropyrimidine-based chemotherapy for patients with MCRC by Health 
Canada in 2005 10, 15. 
The use of bevacizumab along with 5-FU-based chemotherapies a first line treatment for 
patients with MCRC has been investigated in a number of RCTs where the addition of 
bevacizumab has demonstrated increases in OS and PFS, as well as an increased risk of 
grade three of four adverse events when compared to treatment with chemotherapy alone 
47
. Approval of the use of bevacizumab along with chemotherapy by the Federal Drug 
Administration (FDA) was mainly due to the favorable results of combination treatment 
(bevacizumab plus IFL) compared to IFL alone seen in a phase III AVF2107 RCT 64. In 
this study combination treatment led to a 4.4 month increase in the PFS and a 4.7 month 
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increase in OS of patients with MCRC compared to patients who received IFL alone 64. A 
subsequent phase IV clinical trial corroborated similar results and helped to establish the 
use of bevacizumab along with FOLFIRI as an effective treatment strategy in clinical 
practice 9. 
The addition of bevacizumab to the FOLFOX has also been investigated in a number of 
clinical trials. One phase III study found that the addition of bevacizumab to FOLFOX 
resulted in a significant increase of 1.4 months in patient PFS and as well as a statistically 
insignificant an increase of 2.4 months in patients’ OS 7. Another retrospective study 
indicated that the addition of bevacizumab with first-line FOLFOX lead to favorable TTP 
and OS 46.  
The BEAT study examined the safety and efficacy of the use of bevacizumab with both 
FOLFOX and FOLFIRI in MCRC patients who were followed for 43 months in routine 
clinical practice 65. This study found almost identical TTP (11.9 months vs. 12 months), 
median PFS (11.6 months vs. 11.3 months), and a slight increase in the OS of patients 
who received combination treatment with FOLFOX compared to those who received 
combination treatment with FOLFIRI (25.9 months vs. 23.7 months) 65. Similar to the 
Tournigand study, one key difference found by the researchers in the BEAT study was in 
the rate of R0 curative hepatic metastasectomy. Among patients who received each 
treatment, 10.4% patients who received bevacizumab and FOLFOX undergoing the 
procedure compared to only 6.4% of patients who received bevacizumab plus FOLFIRI 
65
. 
 
2.1.2.3 Anti-EGFR Monoclonal Antibodies 
Even with the advances made in the treatment of patients with MCRC, and the 
improvements seen in patients’ prognoses when receiving combination therapy with 
bevacizumab and FOLFOX/FOLFIRI, treatment for the majority of patients is not 
curative. Disease progression is common among patients with MCRC and of all patients 
who receive first-line treatment with approximately 63-70% of patients going on to have 
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subsequent second and third-line treatments 40, 51. After the introduction of bevacizumab, 
other molecular targets were sought after to develop similar therapies that would have the 
potential to further improvements in patient outcomes. 
Both cetuximab and panitumumab are monoclonal antibodies directed towards the 
EGFR. The EGFR is a clinically validated anticancer molecular target which is highly 
expressed in the majority of colorectal cancers 16, 17 . EGFR activation plays an important 
role in the activation of a number of signaling pathways including the RAS/RAF/MAPK, 
and the PI3K/AKT pathways 21, 37, 49, 66 . Activation of these pathways are key to a 
number of processes which, when unregulated, are key to cancer cell growth and 
migration, such as cell proliferation, angiogenesis, inhibition of apoptosis, and metastases 
21, 37, 66
. The EGFR is also known to play a role in resistance to both chemotherapy and 
radiotherapy in cancer patients, as well as an overall decrease in patients OS 58, 66. 
Although cetuximab and panitumumab target the EGFR, EGFR status as determined by 
immunohistochemistry (IHC) has been shown to be an unreliable predictor of patient 
response to EGFR-targeted therapy, as responses to both cetuximab and panitumumab 
have been achieved in patients who did not express EGFR by IHC 25, 31, 35, 49. 
 
2.1.2.4 The Kristen Rat Sarcoma Oncogene and its Importance in 
Anti-EGFR Therapy 
The Kristen Rat Sarcoma Oncogene (KRAS) homolog has been found to play an 
important role in patients’ response to anti-EGFR monoclonal antibodies 21, 24, 31, 32, 38, 39, 
49, 67-71
. The KRAS gene encodes small guanosine tri-phosphate-binding protein which 
acts downstream of EGFR activation and plays an important role in the activation of 
RAF, ERK, and PI3K signaling, serving as an important mediator in the regulation of 
cellular proliferation 21, 37. Multiple studies have found that the presence of a KRAS 
mutation negatively affects the potential efficacy of anti-EGFR therapies, when used as a 
monotherapy, or in combination with standard chemotherapy regimens 13, 23, 24, 33, 38. 
Mutations in codons 12, 13, and 61 of exon 2 of the KRAS gene have been found to be 
associated with resistance to both cetuximab and panitumumab 21, 37. These mutations are 
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present in 30-50% of patients with MCRC and lead to the constituent activation of the 
KRAS oncogene, resulting constant signaling through cell proliferation pathways even 
when the EGFR is blocked by agents such as cetuximab or panitumumab 21, 37. 
Retrospective analysis of the phase II and III randomized clinical trials which examined 
the addition of cetuximab and pantiumumab to either FOLFOX or FOLFIRI as first-line 
treatments for patients with MCRC have confirmed that the benefit of the addition of the 
anti-EGFR monoclonal antibodies is restricted only to KRAS wild-type (KRAS-WT) 
patients 13, 22, 33, 37, 38. 
A recent meta-analysis examined the real-effects of the use of cetuximab and 
panitumumab in first or second line treatment of KRAS WT patients using data from 
seven randomized clinical trials which contained KRAS subgroup analyses 37. This study 
confirmed that cetuximab and panitumumab increased response rate and significantly 
reduced the risk of progression and death in KRAS WT patients 37. In Ontario, the use of 
either cetuximab or panitumumab for patients with MCRC is restricted to only patients 
who are determined to by KRAS-WT28, 29. 
 
2.1.3 Cetuximab and its Use with FOLFOX/FOLFIRI in First-Line 
Treatment 
Cetuximab (Erbitux®) is a chimeric (mouse/human) immunoglobulin G monoclonal 
antibody directed against the EGFR and is currently indicated for use for patients with 
MCRC as a monotherapy in second and third-line settings, and in combination with 
irinotecan as a third-line treatment in KRAS wild type patients in Ontario 29, 58. 
 
2.1.3.1 Cetuximab and FOLFOX 
Two critical RCTs have investigated the addition of cetuximab to FOLFOX in patients 
with MCRC. The “Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic 
Colorectal Cancer (OPUS)” study was a phase II trial that compared the efficacy and 
safety of the addition of cetuximab to FOLFOX4 compared to FOLFOX4 alone in 344 
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patients with MCRC 33.  Within all patients enrolled in the trial the ORR was higher for 
patients who received combination therapy (46% vs 36%) leading to a 52% increase in 
the chance of having a response to treatment in patients receiving cetuximab plus 
FOLFOX4 compared to FOLFOX alone 33.  Amongst all patients enrolled there was also 
a doubling in the R0 resection rate for patients receiving combination therapy 33. No 
significant difference was found in the median OS, with patients receiving combination 
therapy having a median OS of 18.3 compared to 18 months for those patients who 
received FOLFOX4 alone 32. 
 KRAS mutations were found to be present in 43% of the patients enrolled in this study, 
and when the results of the trail were stratified based upon KRAS mutational status the 
differential effects of combination treatment were made clear 32. A clear trend between 
the treatment a patient received and their KRAS mutational status were displayed in 
patients ORR and PFS 32.  In KRAS-WT patients, the addition of cetuximab to 
FOLFOX4 led to increased ORR (57% vs 34%), with a 2.55 fold increase in the chance 
of having a response to treatment, a more than two-fold increase in the R0 resection rate, 
and a 43% reduction in the risk of disease progression when compared to those who 
FOLFOX4 alone 32. PFS for patients receiving combination therapy was 8.3 months 
compared to 7.2 months for patients receiving FOLFOX4 alone 32. A trend toward 
increased OS was also seen in patients who received combination therapy, however this 
increase was deemed to be statistically insignificant (22.8 months vs. 18.5 months) 32.  
Contrary to the results for KRAS-WT patients, for those patients who carried mutations 
in their KRAS gene (KRAS-MT) the addition of cetuximab to FOLFOX4 resulted in a 
lower ORR (34% v 53%), no difference in the rates of R0 resection, and an increase in 
the risk of disease progression with a median PFS of 5.5 months for patients receiving 
combination therapy and 8.6 months for FOLFOX4 alone 32. Overall survival was also 
greater KRAS-MT patients who received FOLFOX4 alone however the difference 
between the two treatments was not statistically significant (13.4 months vs. 17.5 
months) 32. 
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A smaller phase II trial which aimed to evaluate the activity and safety of the addition of 
cetuximab to FOLFOX4 also reported high ORR to combination treatment (64%), a 
median TTP of 10 months, median OS of 22 months, and an observed disease control rate 
of 94% when compared to FOLFOX alone 6. Increased ORR and PFS were also seen in 
KRAS-WT patients receiving cetuximab with FOLFOX6 36. 
The COIN clinical trial was the largest trial examining the addition of cetuximab to 
chemotherapy in the first-line treatment of patients with MCRC 35. This clinical trial did 
not examine the effects of the addition of cetuximab to FOLFOX alone, however 
compared the addition of cetuximab to a number of different oxaliplatin containing 
chemotherapy regimens 35. The investigators compared patients who had either received 
cetuximab along with oxaliplatin and capecitabine, or oxaliplatin with infused 
fluouroracil plus leucovorin (FOLFOX), to patients who received the either 
chemotherapy regimen alone 35. KRAS mutations were present in 43% of patients 
enrolled in this trial, and the within this group of individuals the investigators saw no 
added benefit of the addition of cetuximab to chemotherapy compared to oxaliplatin 
based regimens alone 35. Amongst this patient group there was no evidence of a median 
OS benefit (17.9 months without cetuximab vs 17.0 months with cetuximab), or 
decreased risk of disease progression (PFS 8.6 of months for both groups) 35. The 
addition of cetuximab to oxaliplatin based chemotherapy however did significantly 
increase the ORR for KRAS-WT, with 64% of patients who received cetuximab having 
either a partial or complete response compared to only 57% of patients who received 
chemotherapy alone 35.   
Due to the fact that patients in this clinical trial could have received cetuximab along with 
FOLFOX or oxaliplatin plus capecitabine, the results of this clinical trial do not fully 
capture the potential of combination therapy consisting of FOLFOX and cetuximab for 
KRAS-WT patients. Any potential gain in the addition of cetuximab to chemotherapy 
could be masked by the inherent differences in the outcomes of patients who receive the 
two different chemotherapy regimens. The effects of cetuximab combined with FOLFOX 
on OS and PFS could very well differ from those of cetuximab combined with oxaliplatin 
and capetcitabine. This combination of the results for patients who received the two 
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different chemotherapy regimens with or without cetuximab may have led to the apparent 
lack of advantage of the addition of cetuximab to first-line treatment which had been 
found in other clinical trials. 
2.1.3.2 Cetuximab and FOLFIRI 
The addition of cetuximab to FOLFIRI was investigated in the Cetuximab Combined 
with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) 
multicentre phase III randomized clinical trial and found that combination therapy lead to 
significant reductions in the risk of disease progression 13. In the intention to treat 
population (ITT) the difference median PFS was statistically insignificant with PFS for 
patients receiving combination therapy being 8.9 months compared to 8.0 months for 
patients receiving FOLFIRI alone 13, 30. However in the ITT population, significant 
increases were found in both the ORR and OS of patients who received combination 
therapy, with an ORR of 46.9% and OS of 19.9 months for patients receiving 
combination therapy compared to ORR of 38.7% and OS of 18.6 months for those 
receiving FOLFIRI alone 30. The chance of having a tumor response was 40% higher for 
patients who received combination treatment than that of patients receiving FOLFIRI 
alone 30. The chances of having either R0 hepatatic metastctecomy surgery or complete 
R0 resection were nearly doubled in patients who received combination treatment 30. 
KRAS mutations were present in 37% of the patients enrolled in the CRYSTAL study, 
and once again combination therapy was seen to be more effective in KRAS-WT 
patients. KRAS-WT patients who received combination therapy had a significantly 
reduction in the risk of disease progression (PFS 9.9 months vs. 8.4 months), significant 
increase in ORR (57.3% vs. 39.7%), and significantly improved OS (23.5 months vs. 
20.0 months), as well as increase in the R0 resection rate compared to those patients who 
received FOLFIRI alone 30.  
 In patients who were KRAS-MT the addition of cetuximab to FOLFIRI resulted in no 
clinical benefit with OS, PFS, as well as resulted in the ORR being higher for patients 
who received FOLFIRI alone than those who received combination treatment 30. 
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2.1.4 Panitumumab and its Use with FOLFOX/FOLFIRI in First-
Line Treatment 
Panitumumab (Vectibix®) is a fully human immunoglobulin G2 monoclonal antibody 
which also targets the EGFR and whose binding inhibits TK auto-phosphorylation, tumor 
cell growth, and metastasis 20, 58. Panitumumab differs from cetuximab in that it binds to 
the EGFR with higher affinity than cetuximab, resulting in fewer infusional related 
allergic reactions than cetuximab due to fully human characteristics 20, 58. Panitumumab 
has shown to be effective as a monotherapy for chemo-refractory MCRC patients is 
currently indicated by Cancer Care Ontario for use as a third-line therapy for KRAS wild-
type metastatic colorectal cancer patients 28. As panitimumab is a fairly recent addition to 
the potential treatment options for patients with MCRC, its use in combination treatment 
with FOLFOX and FOLFIRI has not been as extensively investigated. 
2.1.4.1 Panitumumab and FOLFOX 
The “Panitumumab Randomized Trial in Combination with Chemotherapy for Metastatic 
Colorectal Cancer to Determine Efficacy (PRIME)” study was an open-label, multi-
centre, phase III RCT comparing the addition of panitumumab to FOLFOX4 versus 
FOLFOX4 alone 38. KRAS mutations were detected in 40% of the 1183 patients enrolled 
in this trial and once again the effect of the addition of the anti-EGFR antibody to 
chemotherapy differed in wild-type and mutated patient populations 38. In KRAS wild-
type patients, combination therapy was seen to lead to a slight increase in ORR (55% vs. 
48%) and R0 resection rate 38. A favorable increase of 4.2 months was seen in the OS 
(23.9 months vs. 19.7 months) of patients receiving panitumumab with FOLFOX4 
although this increase was not statistically significant 38. A statistically significant 
improvement was seen in the patient PFS, with patients who received combination 
therapy having PFS of 9.6 months compared to 8.0 months for those who received 
FOLFOX4 alone 38.  
The addition of panitumumab to FOLFOX4 demonstrated detrimental effects for those 
patients who were KRAS-MT present 38.  The addition of panitumumab to FOLFOX to 
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these patients resulted in a statistically significant decrease in patient PFS, as those 
patients’ who received combination therapy  had a median PFS of 7.3 months compared 
to 8.8 months for those patients’ who received FOLFOX4 alone 38. OS was also inferior 
for patients receiving combination therapy (15.5 months vs. 19.3 months), while ORR did 
not differ for the two treatment strategies for this patient group 38. 
2.1.4.2 Panitumumab and FOLFIRI 
The largest clinical trial examining the efficacy of panitumumab and FOLFIRI in a first-
line setting was a single-arm, phase II multicentre trial which enrolled 154 patients with 
metastatic colorectal cancer 39. In this trial 59% of the patients were found to be KRAS-
WT and these patients were found to have higher rates of overall response (56% vs. 38%) 
resulting in an odds ratio of 2.1 when comparing KRAS-WT to KRAS-MT patients 39. 
KRAS-WT patients also had increased TTP (11.2 months vs. 7.3 months), as well as PFS 
(8.9 months vs. 7.2 months) with a hazard ratio of 0.5 representing a lower event rate and 
longer time to progression or death for KRAS-WT patients compared to KRAS-MT 
patients 39. There were two important findings in this study. Firstly, the overall response 
rate of 38% seen in KRAS-MT patients was very similar to the response rates found in 
two other studies for patients who received FOLFIRI alone, indicating that the addition of 
panitumumab to FOLFIRI may provide no benefit to KRAS-MT patients at all 39. 
Secondly, was the fact that while the addition of panitumumab to FOLFIRI was shown to 
not benefit KRAS-MT patients, it also was shown not to negatively affect these patients, 
unlike what was seen with the combination of panitumumab and FOLFOX in the PRIME 
study 39.  
Another smaller clinical trial also examined the addition of panitumumab to FOLFIRI in 
first-line treatment of patients with MCRC. This multicentre, open-label, phase II clinical 
trial was also only had one single-arm, only looking at patients who had received 
panitumumab plus FOLFIRI 20.  Twenty-four patients were enrolled in this trial and 
results were not stratified based upon KRAS status 20. Of all of the patients enrolled 33% 
had an overall response, all of them being partial responses 20. Stable disease occurred in 
46% of patients receiving treatment, with median PFS being 10.9 months, and median OS 
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of 22.5 months 20. Combination therapy was also found to be well tolerated by patients, 
with the most common adverse event being skin related toxicity 20. 
The addition of panitumumab to FOLFIRI was also examined in an open-label, 
multicentre, randomized phase III clinical trial as a second-line treatment for patients 
who had initial treatment failure. KRAS mutations were found in 45% of the patients 
enrolled 40. Similar to the study examining panitumumab to FOLFOX, significant 
increases were seen the differences in PFS between those patients who received 
combination therapy and those who received FOLFIRI alone, with an insignificant 
positive trend toward increased OS for KRAS-WT patients who received combination 
therapy, with the opposite being the case for KRAS-MT patients 40. 
 
2.2 The Cost-Effectiveness of FOLFIRI/FOLFOX, 
Bevacizumab, Cetuximab, and Panitumumab in 
Colorectal Cancer Treatment 
The cost effectiveness of the FOLFOX and FOLFIRI chemotherapy regimens as well as 
for bevacizumab, cetuximab, and panitumumab monoclonal antibodies in their use for 
colorectal cancer have been previously investigated in a number of studies in various 
treatment settings. 
The cost-effectiveness of FOLFOX and FOLFIRI chemotherapy regimens for patients 
with unresectable metastatic colorectal cancer was investigated by Tumeh et al. using a 
Markov decision model to compare patients receiving either FOLFOX or FOLFIRI as 
first-line treatment. This study was based upon the phase III clinical trial by Collucci et 
al. in which patients were administered either FOLFOX or FOLFIRI as their first line 
treatment for eight, two week cycles 6.  The costs for hospital and physician services were 
estimated using Centres for Medicare and Medicaid services reimbursement data from 
the United States and utilities were derived from literature 72. A Markov decision model 
was developed to compare patients receiving either FOLFOX or FOLFIRI as first-line 
treatment for patients with MCRC. The investigators then conducted univariate 
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sensitivity analyses on the number of cycles a patient received as well as on each 
probability of patients experiencing adverse events, utility, and costs 72.  
In the base case analysis FOLFOX was found to provide 1.003 QALYs at a cost of 
$29,865 while FOLFIRI provided 0.921 QALYs at a cost of $24,551, resulting in an 
ICER of $65,170/QALY 72. In their sensitivity analysis the investigators found the cost-
effectiveness for FOLFOX compared to FOLFIRI varied from $34,772/QALY when 
patients only received 4 cycles, to $91,968/QALY when patients received 12 cycles. The 
investigators also found that the expected survival associated with the chemotherapy 
regimens, the probability of death following treatment, and the cost of the chemotherapy 
regimens themselves most greatly influenced the resultant ICER 72.  FOLFOX was found 
to be more cost effective when it was associated with an expected survival of 1.28 years 
or greater or when FOLFIRI was associated with less than 1.14 years72. FOLFOX also 
became more cost-effective than FOLFIRI when its cost was below $28,750 and the cost 
of FOLFIRI was less more than $26,040 72.  An additional probabilistic Monte Carlo 
sensitivity analysis on 10,000 patients found that with a willingness-to-pay threshold of 
$50,000/QALY, FOLFOX was more effective and more costly 52.72% of the time and 
more costly and less effective 47.28% of the time, a result indicating that both regimens 
are very similar in terms of effectiveness and cost-effectiveness 72. 
The cost-effectiveness of cetuximab monotherapy for patients with MCRC was 
investigated by Mittman et al. In this study the investigators used data from the National 
Cancer Institute of Canada’s CO.17 study,  an open-label, randomized phase III clinical 
trial where resource utilization and health utility data were collected prospectively 
alongside efficacy data for patients receiving either cetuximab monotherapy plus best 
supportive care, or best supportive care (BSC) alone73. This analysis was conducted in 
the perspective of the Canadian healthcare payer over the time horizon of 18-19 months 
which correlated to the duration of the CO.17 trial 73. The cost of cetuximab was 
determined from the Patented Medicine Prices Review Board of Canada, outpatient as 
well as laboratory and diagnostic costs were determined using the Ontario Health 
Insurance Plan (OHIP) fee schedule, hospital costs were determined using data from the 
Sunnybrook Health Sciences Centre, and adverse event costs were determined using the 
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Ontario Case Costing Initiative and multiplied by the number of each event for each 
patient 73. Sensitivity analyses were carried out on the cost of cetuximab to reflect 
changes in price in different countries, as well as around patient survival 73.  
For the ITT population, patients who received cetuximab in addition to best supportive 
care were found to have a mean average cost of $28,202 per patient with an average of 
0.64LYs and 0.40QALYs compared to an average mean cost of $4,233 with an average 
of 0.52LYs and 0.32QALYs resulting in ICERs of $199,742/LY ($125,973/LYs to 
$652,492/LY) and $299,613/QALY ($187,440/QALY to $898,201/QALY) 73. The 
investigators then focused solely on those patients who were determined to be KRAS-
WT. In this group patients receiving combination therapy had an average mean cost of 
$37,324 with average gains of 0.79LYs and 0.51 QALYs, while those who received BSC 
had an average cost of $3,707 with average gains of 0.51LYs and 0.33QALYs resulting 
in ICERs of $120,061/LY ($88,679/LY to $207,075/LY) and $186,761/QALY 
(130,326/QALY to $334,940/QALY) 73. Cost-effectiveness acceptability curves showed 
a 0% probability of the cost-effectiveness of cetuximab falling below the standard 
threshold of $50,000/LY and $50,000/QALY, therefore concluding that cetuximab may 
not represent a cost-effective option over best supportive care alone 73.  
The cost effectiveness of combination therapy consisting of cetuximab and irinotecan 
along with BSC compared to best supportive care was investigated by Starling et al.  This 
analysis which was undertaken in the perspective of the National Health Service (NHS) 
in the United Kingdom used combined data from two clinical trials, one trial investigated 
the use of cetuximab plus BSC, and the other examined the addition irinotecan plus BSC 
in patients with MCRC 74. Patient costs and consequences were determined over a 
lifetime time horizon and direct patient costs were determined from the NHS 74.  For 
patients receiving combination of cetuximab and irinotecan the average cost was 
determined to be £22,270 with a discounted life expectancy of 0.91LYs while patients 
receiving BSC had an average total cost of £3,368 and 0.472 discounted LYs 74. 
Tappenden et al investigated the cost-effectiveness of the addition of bevacizumab to 
either irinotecan plus 5-FU and leucovorin (IFL) or 5-FU and leucovorin (5-FU/LV) 
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alone in first-line treatment of patients with MCRC in England and Wales. The 
investigators developed a decision-analytic model with three states where patients could 
either be alive and progression free, alive with progressive disease, or dead, with patient 
quality of life varying between the different states 75. In this model all patients entered 
into the alive and progression free state where they would receive bevacizumab plus 
either IFL or 5-FU/LV alone 75. The model was based on effectiveness data from two 
clinical trials; the AVF2107G phase III clinical trial which investigated bevacizumab + 
IFL versus IFL alone, and the phase II AVF2192G randomized clinical trial which 
compared bevacizumab plus 5-FU/LV versus 5-FU/LV alone 75. Bevacizumab-specific 
quality-of-life data could not be found so researchers assumed a utility value of 0.8 for 
patients who did not have disease progression, 0.60 for patients who had progressive 
disease, and 0 for patients who were dead 75.  Drug unit costs used in the analysis were 
taken from the British National Formulary and other hospital, pharmacy, diagnostic, 
physician, and palliative care costs were found via literature review 75. 
 IFL treatment alone was found to have a mean cost of £23,779 with 1.57LYs and 1.13 
QALYs gained while the addition of bevacizumab to IFL was found to have a mean total 
cost of £43,140 with a mean of 1.98 LYs and 1.44 QALYs gained, resulting in ICERs of 
£46,853/LY and £62,857/QALY 75. 5-FU/LV treatment was found to have a cost of 
£21,459 with a mean gain of 1.41LYs and 1.01QALYs, while the addition of 
bevacizumab to 5-FU/LV resulted in a mean cost of £37,074 with average gains of 
1.59LYs and 1.19QALYs resulting in ICERS of £84,396/LY and £88,436/QALY 75. The 
investigators found that the key determinant of the cost-effectiveness of combination 
therapy with bevacizumab was acquisition cost of bevacizumab, however even with 
varying acquisition costs that combination therapy was unlikely to be below the standard 
threshold value of £60,000/QALY used by the NHS in the United Kingdom 75. 
Asseburg et al. investigated the cost-effectiveness of combination therapy consisting of 
cetuximab and FOLFIRI to bevacizumab plus FOLFOX for KRAS -WT patients with 
initially unresectable metastases limited to the liver in a German setting. In this study the 
investigators carried out an indirect comparison using available clinical trial data and 
extrapolated them to a 10 year time horizon 76. All patients in this model entered in the 
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metastatic colorectal carcinoma: monoclonal antibody state, from here patients could 
move to chemotherapy following progression or no chemotherapy after R0 resection 
states 76. Patients who progressed to subsequent chemotherapy could then move to best 
supportive care and death while patients who had undergone successful R0 resection 
could then move to healed or death states. Efficacy data was collected from randomized 
controlled trials involving KRAS-WT patients with metastatic colorectal cancer who 
received cetuximab or bevacizumab with either chemotherapy regimen after which 
indirect meta analysis of survival outcome, discrete event simulations were carried out to 
combine data from the different sources 76. This analysis was carried out in the 
perspective of the German statutory health insurance plan; costs for the active treatments 
were estimated from German Lauer-Taxe guidelines, ambulatory and physician service 
costs were calculated using the German Uniform Valuation Scheme; while inpatient costs 
for grade 3 and 4 adverse events were calculated using diagnosis related groups 
multiplied with the current German DRG value 76. Sensitivity analyses were then carried 
out to account for uncertainty with estimates of OS, PFS, differing rates of R0 resection, 
and exploring how the cost-effectiveness of combination therapy with cetuximab 
compared to bevacizumab would differ if both FOLFOX and FOLFIRI were available at 
the same cost 76. 
In the base cases analysis first line treatment with cetuximab was found to have an 
overall lifetime discounted cost of €99,134 with an expected total of 2.88 discounted LYs 
gained while treatment with bevacizumab was found to cost €91,563 with 2.38 
discounted LYs gained, leading to an ICER of €15,020/LY 76. Sensitivity analyses 
surrounding estimates of OS and PFS resulted in ICER values of between €3,806 - 
€24,660/LY. When the investigators conducted sensitivity analysis surrounding the 
proportion of patients successfully undergoing an R0 resection after treatment to 34% for 
patients receiving cetuximab and 15.4% for patients receiving bevacizumab the resultant 
ICER decreased to €9,170 76. When the investigators carried out the analysis with both 
FOLFOX and FOLFIRI having the same costs, treatment with cetuximab was found to 
have an ICER of  €7,560/LY 76. 
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The cost-effectiveness of the use of cetuximab, panitumumab, and bevacizumab along 
with chemotherapy for KRAS-WT metastatic colorectal cancer patients has been 
investigated with the perspective of the UK NHS 77. In this evaluation the investigators 
developed a semi-Markov model to simulate long-term patient outcomes for patients after 
receiving either combination as a first-line treatment. The model was parameterized using 
data from the CRYSTAL and PRIME clinical trials, with drug, physician cost, scans, 
hospitalizations and treatment of adverse event data compiled to determine patient 
resource utilization 77. Sensitivity analyses were then carried out to determine the 
robustness of the results. In the base case the ICER for cetuximab and FOLFIRI versus 
FOLFIRI along was £30,665 QALY, £28,626/QALY when compared to bevacizumab 
plus FOLFOX, and £15,326 when compared to panitumumab to FOLFOX.  From this 
analysis the investigators determined that the combination treatments fell within the 
commonly used willingness to pay threshold for cost-effectiveness in the UK and the 
main drivers of the ICER were the number of patients undergoing R0 resections as well 
as the acquisition costs of the monoclonal antibodies 77. 
This study differs from the previously conducted cost-effectiveness analyses as it aims to 
determine the cost-effectiveness of the use of combination treatment consisting of either 
cetuximab or panitumumab with FOLFIRI within the Canadian health care system. In 
this study health care costs were found using patient-level data from administrative 
databases in the province of Ontario to capture the actual cost to the healthcare payer. In 
this study I use a semi-Markov model where the Markovian assumption is relaxed and the 
transition probabilities of progression from one state to another vary dependent upon a 
patients time in that state. This is able to capture the changes in the risk of progression 
over time. This study is also the first cost-effectiveness analysis to investigate the cost-
effectiveness of the use of panitumumab plus FOLFIRI or FOLFOX when it is used as a 
first-line treatment. 
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2.3 Research Question 
To determine whether treatment starting with first-line combination therapy consisting of 
either cetuximab or panitumumab plus FOLFIRI chemotherapy represent cost-effective 
treatment options compared to the current clinical practice of the use of combination 
bevacizumab plus FOLFIRI as first-line treatment for patients with Metastatic Colorectal 
Cancer from the perspective of the Ontario healthcare payer. 
 
3 Chapter 3: Methods 
3.1 Methods 
I developed a decision analytic model to project the lifetime clinical and economic 
consequences of patients receiving combination therapy in the first line. The combination 
therapy consists of either cetuximab or panitumumab plus FOLFIRI compared to the 
current standard of care of combination bevacizumab plus FOLFIRI for use in first-line 
treatment for patients with MCRC in the province of Ontario. 
3.2 Model Overview 
I developed decision tree analytic model to compare the projected lifetime clinical and 
economic consequences of MCRC patients receiving combination therapy in the first-line 
through the course of their disease. The decision tree consists of three different arms each 
representing one of the possible combination therapy regimens. At the end of each arm is 
a Markov model representing the treatment strategies used in current clinical practice for 
MCRC patients as their disease progresses. Model M1 represents the treatment strategy 
of patients receiving combination therapy consisting of bevacizumab and FOLFIRI, M2 
the strategy for receiving cetuximab and FOLFIRI, and M3 the strategy for receiving 
panitumumab and FOLFIRI (Figure 3.1). Each model represents the potential treatment 
course a patient would receive over the course of their disease. In the case of patients 
receiving bevacizumab plus FOLFIRI model M1 represents the treatment course that is 
used in current clinical practice for patients with MCRC in Ontario. Models M2 and M3 
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represent the alternative treatment courses starting with first line cetuximab or 
panitumumab plus FOLFIRI. To date no RCT has investigated the effectiveness of these 
three treatment strategies head-to-head in this patient population. Therefore, analysis was 
conducted through indirect comparison using efficacy data from RCTs relevant to each 
treatment option used in these models. Each Markov model had a Markov termination 
condition and was run for a time horizon of 100 months. This Markov termination 
condition was selected to capture the entire expected lifetime for patients with MCRC. 
This decision analytic model was constructed using TreeAge Pro Suite 2009™. 
 
Figure 3.1: Schematic of the Decision Analytic Model 
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3.3 Data Sources 
I used data from both administrative databases from the province of Ontario as well as 
efficacy data from 5 randomized clinical trials. Patient level data for patients diagnosed 
with MCRC between January 1st 2008 and December 31st 2010 were compiled by the 
Institute of Clinical Evaluative Sciences (ICES) Ontario Cancer Data Linkage Program 
(cd-link). This program linked anonymized patient level data from the Ontario Cancer 
Registry (OCR), Ontario Health Insurance Plan (OHIP), Ontario Drug Benefit  Claims 
(ODB), Canadian Institute for Health Information Discharge Abstract Database (CIHI –
DAD), Canadian Institute for Health Information National Ambulatory Care Reporting 
System (NACRS), Home Care Database (HCD), and Cancer Care Ontario New Drug 
Funding Program (NDFP) databases. 
Efficacy data were taken from four stage III and one stage IV randomized clinical trials 
which all examined the effectiveness of different therapies along the treatment course of 
patients with MCRC. The BEAT study was a phase IV RCT which compared the safety 
and efficacy of combination therapy consisting of bevacizumab with FOLFOX, 
FOLFIRI, or XELOX, which consists of capecitabine plus oxaliplatin, in first-line 
treatment for patients with MCRC 65. The CRYSTAL study investigated the efficacy of 
the addition of cetuximab to FOLFIRI in first-line treatment of patients with MCRC 30. 
The PRIME study examined the efficacy of the addition of panitumumab to FOLFOX as 
first line treatment 78. The ECOG E3200 trail was used to determine the efficacy of the 
use of FOLFOX in second-line treatment for patients with MCRC 12 , while an open label 
phase III trial was used to determine the overall survival of patients receiving best 
supportive care alone in third-line treatment settings 41.  
The model was parameterized using data collected from the selected phase III and IV 
randomized clinical trials as well as from data from administrative databases in the 
province of Ontario. Patient-level data were made available by the ICES Cd-link program 
which finds cases of cancer from the OCR and links these cases to cancer-relevant 
information from other health administrative databases.  This enabled us to capture data 
from the OCR, NDFP, OHIP, ODB, NACRS, CIHI-DAD, and HCD databases. 
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3.3.1 Validation of Data Sources 
The OHIP, CIHI-DAD, and OCR administrative databases have been shown to 
accurately represent the general population of patients diagnosed with a specific disease. 
The OHIP and CIHI-DAD databases have been shown to accurately identify those 
patients with hypertension from a population sample 79. This was achieved through 
comparing the rates of hypertension determined through the use of multiple algorithms in 
the administrative databases and comparing them to patient charts reviewed from family 
practices in Ontario 79.  A validation of the OCR determined that the registry was 
effective in capturing cancer cases in the province of Ontario with 98% sensitivity, while 
another study which aimed to determine the accordance between cause of death data from 
the OCR compared to a cohort of patients followed in a prospective cohort study found 
very high levels in the abstraction techniques of the OCR, with the database having high 
sensitivity and specificity 80, 81. 
The coding accuracy of these databases plays an important role in ensuring that the 
patient cohorts derived from these databases are truly reflective of the population of 
interest. The coding accuracy of the CIHI-DAD database has previously been studied for 
patients with cardiac diagnoses, and was found to have high specificities but quite 
variable sensitivities 82. Austin et al. found that myocardial infarction which has clearly 
defined clinical criteria was found to have both high sensitivity and specificity, while 
those diseases which had less clearly defined clinical criteria and whose diagnoses could 
be affected by inter-observer variability tended to have lower specificities 82. For a patient 
to be diagnosed with colorectal cancer their physician would have ordered blood tests, 
imaging studies, as well as biopsy to confirm the diagnoses, thus minimizing the chances 
of a patient having a false-positive diagnosis 83. Given the clear diagnosis criteria for 
colorectal cancer we can assume that the CIHI-DAD would also have high specificity and 
sensitivity for capturing patients with MCRC. 
29 
 
 
3.3.2 Cohort of Interest 
An initial data request was made to Cd-Link in October 2011 for all incident cases of 
colorectal cancer who had an ICD9 diagnosis code of 153.1-9, 154.0, or 154.1 who had 
been diagnosed between January 1st 2008 and December 31st 2010 as to capture a period 
when all three drugs of interest had been approved for funding by CCO.  Ethics approval 
for the project was granted by the University of Western Ontario’s Research Ethics Board 
in October 2011. The patient-level data provided from ICES were received in May 2012 
and included data for 22,610 cases of colorectal cancer. 
To conduct both survival and cost analyses on a patient cohort which was similar in both 
patient-level and clinical trials, patients of interest had to be selected from the initial 
22,610 cases of colorectal cancer. From this cohort of patients I was interested in those 
patients who had MCRC and whose first-line treatment consisted of combination 
bevacizumab and FOLFIRI. I focused on patients receiving this bevacizumab plus 
FOLFIRI as first-line treatment. Treatment strategies consisting of either cetuximab plus 
FOLFIRI, or panitumumab plus FOLFIRI are not indicated or funded for use in the first-
line by CCO and thus I expected to not find any cases of patients receiving either of these 
combination treatments. I was able to identify these patients specifically through the use 
of the NDFP database which provided both disease stage and treatment information. 
Patients were selected if for their unique subject identifier there was at least one record in 
their disease variable of “metastatic colorectal cancer-1st line”. I then narrowed down this 
group to only include those patients who received both combination bevacizumab and 
irinotecan on the first day of treatment for metastatic colorectal cancer. This inclusion 
criterion resulted in 1,706 patients who received first-line bevacizumab plus FOLFIRI. 
 For this analysis only those patients who were diagnosed in the 2008 or 2009 were used 
to ensure that there would be at least two years of follow up data from the first date of 
treatment. This resulted in a final cohort consisting of 1216 patients. The KRAS status of 
the patients in the cohort of interest was not able to be determined from the CD-link data 
sources. To facilitate the comparison of the three treatment strategies the assumption was 
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made that all patients in the cohort were KRAS-WT.  This assumption does not affect 
patient outcomes as patient’s response to both bevacizumab and 5-fluorouracil containing 
chemotherapy regimens have previously been shown to be independent of patient KRAS 
status 64, 84-86. Important characteristics of these patients are presented in Table 3.1.  
Table 3.1: Cohort Patient Characteristics N=1216 
Diagnosis Year % 
2008 50.40 
2009 49.60 
  
Sex % 
Female 39.94 
Male 60.06 
  
Age Category % 
Under 50 15.61 
50-54 13.18 
55-59 15.32 
60-64 18.21 
65-69 14.96 
70-74 14.57 
75+ 8.14 
  
Primary Site of Tumor % 
Colon 63.08 
Rectum 27.22 
Other 9.7 
  
# of Metastatic Sites  % 
1 79.40 
>1 20.60 
  
Height 169.0 cm ± 11.9 
  
Weight 74.8 kg ±16.8 
  
Drug Received % 
Bevacizumab 100 
Irinotecan 100 
Oxaliplatin 38.1 
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Panitumumab 8.4 
Cetuximab 5.6 
Once the cohort was identified I was able to track what treatments each patient received 
over the course of their disease. Of the 1216 patients who received first-line bevacizumab 
and FOLFIRI a total of 99 patients received all three lines of treatment within the two 
years of follow up.  Of the patients who received first-line treatment, 25.03% remained 
receiving first-line treatment without progressing to receive subsequent lines of treatment 
while 8.9% died during the course of first line treatment.  The majority of patients went 
on to receive later lines of treatment with 46.07% received second line treatment.  
Approximately 5% of patients went on to receive monotherapy panitumumab after their 
first line treatment, while 14.97% moved directly to receive BSC (Figure 3.2).  
 A total of 440 patients received second-line treatment with FOLFOX. Of these patients a 
total of 17.83% did not progress and remained receiving second-line treatment within two 
year s from the commencement of first-line treatment. An equal number of patients 
(17.83%) died during this line of treatment. Approximately 44% of patients moved on to 
receive third-line panitumumab monotherapy while 20% went directly to receive BSC 
(Figure 3.2).  
 One hundred and sixty two patients received third-line panitumumab.  Of these patients 
9.26% remained in third-line, 14.43% died while receiving treatment, and 75.31% moved 
on to receive BSC. For patients who received BSC, the proportion of patients who 
remained in state without dying and the number of patients who died varied depending on 
what line of treatment they entered in from. The percentage of patients who remained in 
BSC was highest for those patients who entered from first-line (35.4%). This value 
decreased to 22.22% for patients who entered from second-line and further fell to 18.3% 
for those individuals who entered from third-line. The percentage of patients who died 
increased as patients entered BSC from later stages in treatment. Approximately 65% of 
patients who entered BSC from first-line treatment died within the follow-up period. This 
value increased to approximately 78% for patients entering from second line and 82% for 
patients entering from third-line (Figure 3.2).   
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The time that each patient spent in each state was able to be determined from the disease 
and treatment date variables available in the NFP databse. Palliative care fee-codes were 
found in the Ontario physician schedule of benefits. The start of the best supportive care 
state was determined to be the first day that a palliative care fee-code was claimed in the 
OHIP database after the final date a patient had received their last treatment. 
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Figure 3.2: Schematic of the Treatment Courses Taken by Patients in the Cohort of 
Interest Over 24 Months. 
 
 
3.3.3  The Economic Burden of Disease 
The economic burden on the payer for patients with MCRC was found for the 1216 
patients in the cohort of interest. Each patient’s treatment course was determined using 
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the data provided in NDFP and OHIP databases and were then grouped according to the 
treatment courses they received. Each patient’s clinic, homecare, hospital, OHIP, ODB, 
and NDFP drug costs were found from the date of diagnosis up until they died or until the 
end of data availability. The average cost for each database as well as total overall cost 
for each observed treatment course was then found. 
 
3.3.4 Patient Characteristics from Randomized Control Studies 
 The demographic and baseline characteristics of the patients enrolled in the five RCTs 
used in this analysis are similar to those found in the cohort of interest. Median age, age 
range, and percentage of male and female patients were consistent across all five RCTs. 
Amongst the three first line trials, patient information on the primary site of tumor, as 
well as the number of metastases and sites of metastatic disease were consistent.  To 
ensure that the results of these clinical trials could be used to model the progression of the 
patients of interest it was important that each clinical trial had similar enrollment criteria. 
The similarity of patients between the studies allowed for the use of the different trials to 
model the different treatment regimens used as patients disease progressed. In each of 
these trials enrollment was  dependent upon patients being older than 18 years old, 
diagnosed with histologically confirmed MCRC, and were scheduled to receive 
fluoropyrimidine-based chemotherapy as the first-line treatment strategy 13, 30, 38, 65. In all 
three trials patients were able to be included in the study if they had received previous 
chemotherapy for colorectal cancer but had not received any previous treatment for 
metastatic disease.  
 Another important similarity between the three first-line trials which was necessary to be 
able to compare the results of the three possible treatment options was that all three trials 
only included patients with an Eastern Cooperative Oncology Group (ECOG) 
performance status of 2 or less. The ECOG was one of the first cooperative groups 
created to perform multi-centre randomized clinical trials of cancer therapies and 
introduced the ECOG performance status scale in 87. The ECOG performance status or 
ECOG WHO is a scale ranging from 0 to 5; 0 indicates the best scenario where a patient 
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is fully active and is able to carry on all the activities he\she would be able to do before 
having the disease and 5 represents dead 87, 88. This scale is widely used by clinicians in 
oncologic practice because it correlates patient survival duration, response to treatment, 
quality of life, and comorbidity 87, 88 and provide insight into how a patient’s disease is 
progressing , how disease affects patients’ daily living abilities, and to determine a 
patient’s suitable treatment options 87, 88. 
In the E3200 and Open Label Phase III the percentage of patients in each ECOG 
performance status starts to differ from those seen in the first line trials, however this is to 
be expected as these trials examine treatment options in patients who have had more 
progressive disease and thus we would expect to have greater percentages of patients in 
these higher ECOG states.  
Table 3.2: Randomized Clinical Trial Demographics and Baseline Characteristics 
Trial BEAT 
CRYSTAL * 
KRAS WT 
Population 
Regimen Bevacizumab + FOLFIRI 
Bevacizumab 
+ FOLFOX 
Cetuximab + 
FOLFIRI 
Line 1st 1st 1st 
    
Age, Years 
   
Median 59 59 61 
Range 25-82 21 – 85 24-79 
    
Sex, % 
   
Male 61 60 62 
Female 39 40 38 
    
ECOG 
Performance 
Status, %    
0 65 69 57.9 
1 35 31 38 
2 n/a n/a 4.1 
    
Primary site of 
tumor, %    
Colon 65 61 55.2 
Rectum 28 26 44.2 
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Colon and Rectum 7 13 0.6 
    Site of Metastatic 
Disease %    
Liver 70 69 n/a 
Lung 31 28 n/a 
Other 29 25 n/a 
    
Number of 
metastatic sites, %    
1 61 63 
* 87.7% had 
metastases at one 
or two sites 
>1 39 38 
 
    
Prior Adjuvant 
Chemotherapy % 44 36 23.3 
Trial 
PRIME *KRAS 
WT Population ECOG E3200 Open Label III CO. 17 
Regimen 
Panitumumab + 
FOLFOX FOLFOX 
Panitumumab + 
BSC BSC 
Line 1st 2nd 3rd BSC 
     
Age, Years 
    
Median 62 60.8 62 63.6 
Range 27-85 25-84 27-82 28.7 - 85.9 
     
Sex, % 
    
Male 67 60.8 63 63.9 
Female 33 39.2 37 36.1 
     
ECOG 
Performance 
Status, %     
0 * 94% of patients 
were  ECOG 0/1 51.2 46 22.5 
1 * 94% of patients 
were ECOG 0/1 43 41 54 
2 6 5.8 13 23.5 
     
Primary site of 
tumor, %     
Colon 66 n/a 66 56.5 
Rectum 34 n/a 34 24.6 
Colon and Rectum n/a n/a n/a 18.9 
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     Site of Metastatic 
Disease     
Liver 69 75.9 n/a 81.8 
Lung n/a 51.2 n/a 63.2 
Other 12 n/a n/a 55.5 
     
Number of 
metastatic sites, %     
1 21 n/a n/a 18.6 
>1 78 n/a n/a 81.4 
     
Prior Adjuvant 
Chemotherapy % 16  100 36.1 
 
 
3.4  Detailed Description of Model 
3.4.1 Model M1: Bevacizumab + FOLFIRI 
 Model M1 has six states: (1) first-line combination treatment with bevacizumab plus 
FOLFIRI, (2) a cancer-free state resulting from surgery for metastases (3) second-line 
treatment with FOLFOX (4) third-line treatment with monotherapy panitumumab, (5) 
best supportive care, and (6) death (Figure 3.3).  
38 
 
Figure 3.3: Schematic of Markov Model M1 
 
 In Model M1 patients receiving first-line bevacizumab can move to receive FOLFOX, 
panitumumab monotherapy, or best supportive care states based on transition 
probabilities from the PFS estimates derived from the patient level data and the observed 
treatment courses observed in the cohort of interest. Patients can transition to death using 
transition probabilities determined from age-dependent mortality estimates for patients 
aged 61, the average age of patients enrolled in all first line clinical trials. These mortality 
estimates were then weight-adjusted by sex by multiplying the percentage of patients of 
each sex by the sex-dependent mortality estimate for each year.  It is also possible for 
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patients receiving first-line combination treatment to have a very good response to 
treatment which leads them to be able to have surgical resection of their metastases. The 
rate of surgical resections was provided over the course the clinical trial was published in 
the BEAT trial 65. To determine the monthly probability of a patient undergoing surgical 
resection this rate was divided by the length of the trial. The resultant value was then 
used as the monthly probability of undergoing surgical resection and thus of moving to 
the cancer free state. 
Patients who move to the cancer-free state can have a recurrence of their disease. It was 
assumed that those patients who had a recurrence of disease would move to have second-
line treatment and this transition was determined from a retrospective review of patients 
who underwent resection conducted by Tomlinson et al. This transition occurred in a time 
dependent manner with more patients experiencing recurrence before 5 years survival 
than after 5 years of survival. Patients who did not have a recurrence of disease could 
then either remain in the healthy cancer-free state, or could transition to the death state 
via transition probabilities determined from OS estimates which were obtained in the 
same retrospective study 89. 
For patients who move on to receive second line treatment, they can then transition to 
receive third line panitumumab monotherapy or best supportive care, using estimates of 
PFS or to death using time-dependent transition probabilities. The PFS estimate was used 
for second line treatment with FOLFOX 90. Transitions from second-line chemotherapy 
to death occurred via age-dependent background mortality or due to death resulting from 
toxic adverse reaction to treatment 90.  
Patients receiving third line panitumumab can transition to the best supportive care or to 
death via disease-specific using transition probabilities determined from the PFS estimate 
for KRAS-WT patients from Van Cutsem et al. 38 or age dependent background 
mortality. Patients can enter the BSC state from either first, second, or third line stages 
and transition to the death state using transition probabilities determined from OS 
estimates for KRAS-WT patients derived from Jonker et al. 34. 
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In models M1, M2, and M3 the transition to death was determined from either mortality 
data provided in the randomized control trials or from age-dependent mortality estimates 
for patients aged 61 determined from the life table for Ontarians between years 2000 to 
2002, as the mortality rate was unable to be determined from the patient-level data. 
3.4.2 Model M2: Cetuximab + FOLFIRI 
Model M2 has five states: (1) first-line combination treatment with cetuximab plus 
FOLFIRI, (2) a cancer-free state resulting from surgery for metastases (3) second line 
treatment consisting bevacizumab plus FOLFOX, (4) best supportive care, and (5) death 
(Figure 3.4). 
Figure 3.4: Schematic of Markov Model M2 
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In model M2 patients receiving first-line cetuximab and FOLFIRI can transition to either 
second-line treatment, BSC, or cancer free based upon transition probabilities based data 
estimates from Van Cutsem et al. 30, or death via age-dependent background mortality 
determined from statistics Canada 91. Patients who move to the cancer-free transition in 
the same manner as in model M1 and either have a recurrence of disease and move to 
have second-line bevacizumab and chemotherapy, remain cancer-free, or die via age-
dependent mortality 92, 93. Patients who transition to receive second line bevacizumab plus 
FOLFOX can then move on to receive BSC using time dependent transition probabilities 
derived from Giantonio et al. 90, or to death  via a fatal toxicity related adverse event or 
via age-dependent background mortality. Those patients who are in the BSC state then 
transition to the death state using transition probabilities determined from OS estimates 
for KRAS-WT patients derived from Jonker et al.34. 
3.4.3 Model M3: Panitumumab + FOLIRI 
Model M3 has five states: (1) first-line combination treatment with cetuximab plus 
FOLFIRI, (2) a cancer-free state resulting from surgery for metastases (3) second line 
treatment consisting bevacizumab plus FOLFOX, (4) best supportive care, and (5) death 
(Figure 3.5). 
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Figure 3.5: Schematic of Markov Model M3 
 
Model M3 is much like model M2, the only difference being that patients receiving first-
line panitumumab and FOLFIRI can transition to either second-line chemotherapy or 
BSC from transition probabilities based upon PFS estimates, or to the cancer-free state 
from data provided by Douillard et al. 38.  It was assumed that the progression of patients 
receiving pantiumumab plus FOLFIRI would be no different than that of patients 
receiving panitumumab plus FOLFOX given both regimens have been found to be 
equivalent in terms of their effects on patient PFS and OS 5, 6. 
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3.5 Survival Analysis & Transition Probabilities 
The monthly transition probabilities used in the model to move patients between states 
were based upon PFS estimates of first-line treatment from determined from the patient 
level data, as well as estimates of PFS and OS from the published RCTs. The PFS 
estimate for patients receiving first-line bevacizumab and FOLFIRI was determined using 
data provided in the NDFP database. The assumption was made that a change in 
treatment would be indicative of disease progression. By determining the number of days 
from when the patient started first-line treatment to the commencement of their 
subsequent treatment line it was possible to determine whether a patient had progressed 
to either second, third, or best-supportive care or was continuing to receive first-line 
treatment. This was done for a two year window from the first day of treatment for each 
patient. If a patient was still receiving first line treatment at the end of the two year period 
they were considered censored. The Kaplan-Meier survival curve of patient PFS was then 
constructed from the patients in the cohort of interest (Figure 4.7). Weibull distributions 
were similarity fit to PFS estimates found from the NDFP data for patients receiving 
second-line FOLFOX/FOLFIRI, third-line treatment consisting of panitumumab 
monotherapy or combination cetuximab plus irinotecan, and for best supportive care to 
extrapolate survival outside of time period captured. These were then used to model the 
outcomes of patients receiving bevacizumab + FOLFIRI in the comparison of RCT 
versus patient-level data parameterized models. 
Weibull distributions were also fit to Kaplan-Meier survival curves of patient PFS  that 
were  taken from the RCT’s from patients receiving first-line cetuximab plus FOLFIRI 
and panitumumab plus FOLFIRI, second –line  FOLFOX and FOLFOX plus 
bevacizumab, and  third-line panitumumab montherapy, while a Kaplan-Meier survival 
curve for OS was taken from patients receiving best-supportive care alone30, 38, 41, 90. 
These estimates were used then in the base case model. 
Data from the survival curve and the number of patients at risk at given monthly intervals 
allowed for Weibull distributions to be fit to each survival curve. In order to determine 
the number of events and censored cases the assumption had to be made that all 
progression, death, or censoring events would occur at the same time in the month. The 
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number of patients having disease progression or dying was able to be determined   using 
the equation: Number of events = [S(t)-S(t+1)]* Nt. The number of patients who were 
censored in this time period could then be determined by using the equation: Number of 
Censored = Nt-Nevents-Nt+1. With this information it was possible to develop a parametric 
regression model using Weibull distributions to each survival curve. The regression gave 
estimates of the Weibull scale (σ) and shape (β) parameters which were then used in the 
equation S(t)=exp{- (σ/ t)β}  to model survival until there were no more patients in-state 
94
. From this data the monthly transition probabilities were able to be determined.  
The parametric Weibull model is often used to estimate survival at time points after the 
end of a RCT 94 and has previously been used to estimate survival in a CEA of oxaliplatin 
and capecitabine for patients with stage III colon cancer 95. Gerdtham and Zethraeus 
looked at the use of different parametric survival models to predict survival outside of a 
clinical trial of patients who received enalapril versus placebo and compared these results 
with these patients observed true survival 96. In this study the Weibull model was found 
to best predict survival of those individuals who received treatment with enalapril, with 
the exponential model being found to underestimate survival and the gamma and log-
normal models found to overestimate survival 96. To ensure that the Weibull model was 
an appropriate choice to model patient survival, I compared the model fit of the Weibull 
and exponential models to the PFS data for patients receiving first-line bevacizumab and 
FOLFIRI. The Weibull model was found to have a higher log-likelihood value as well as 
lower AIC and BIC values compared to the exponential model, thus indicative of the 
Weibull better fitting the survival data (Table 3.3).Also, the use of the Weibull 
distribution was a more attractive option to fit the survival data as it allows the hazard 
rate to increase or decrease over time, while the exponential model assumes constant 
hazard rate over time. 
 The monthly transition probabilities were then determined from the Kaplan-Meir curves 
constructed from the parametric models. Transition probabilities for a cycle of one month 
were determined using the 
formula: 	

  1     !!
 "
!. The monthly 
percentage of patients` receiving surgery for the removal of metastases of R0 hepatic 
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metastectomy, as well as the occurrence of grade 3 or 4 adverse events was determined 
by first converting the probability of surgery over the course of the RCT to a monthly rate 
using the formula: #$  1 % &'() *'++()(,!!
# &'() ."
   with trial months being the 
median follow-up. This value was then converted to a monthly transition probability of 
having that event using the 
formula:  	

  1  /0 #$!. 
Table 3.3: Model Fit Statistics 
Model Log-Likelihood AIC BIC 
Weibull -1605.17 3214.35 3224.56 
Exponential -1656.32 3314.64 3319.74 
 For second-line PFS estimates for patients receiving FOLFOX and FOLFOX + 
bevaciuzmab, Weibull distributions were not able to be fit to the survival curves data on 
the number of patients at risk each month were not provided in the RCT 90.  Transition 
probabilities were derived directly from the PFS survival curves for the duration of the 
trial. For months where the monthly transition probability was found to be zero, the value 
of the previous month was used as these transition probabilities are an artifact of the 
clinical trial and it is not plausible to assume that no patients would progress during a 
certain month. Outside the time-horizon of the trial survival was extrapolated using the 
average of the transition probabilities in the last four months of the clinical trial.   
3.6 Health State Utilities 
Utilities for each state were found through a search of the relevant literature 73, 97-101. The 
utility decrement of patients experiencing adverse events associated with each treatment 
option was assumed to be taken into account in these utility values.  The utility values 
used in this analysis can be found in Table 3.4. 
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Table 3.4: Health State Utilities 
Treatment Range Base Case Value 
Sensitivity 
Analysis Range Source 
First-line Bevacizumab + 
FOLFIRI/FOLFOX (with 
adverse events) 
0.80-0.77 0.77 ± 0.20 99, 102
 
 
 
  
First-line Cetuximab + 
FOLFIRI/FOLFOX (with 
adverse events) 
0.80-0.77 0.77 ± 0.20 101, 103
 
 
 
  
First-line Panitumumab + 
FOLFIRI/FOLFOX (with 
adverse events) 
 
0.778 ± 0.20 97
 
 
 
  
Second-Line FOLFOX (with 
adverse events) 
 
0.756 ± 0.20 97
 
 
 
  
Third-Line Panitumumab (with 
adverse events) 
 
0.72 ± 0.20 98
 
 
 
  
Best Supportive Care  
0.68 ± 0.20 98
 
Cancer Free  
0.84 ± 0.20 100
 
Dead  0 
  
3.7 Costs 
Costs used in this analysis were estimated from the perspective of the Ministry of Health 
and Long-Term Care (MOHLTC), the public health care payer in the province of 
Ontario. Only direct medical costs presented in 2012 Canadian dollars were included in 
the models. Costs prior to 2012 were adjusted for inflation to 2012 Canadian using the 
consumer price index for healthcare in Ontario 104. Indirect medical costs were not 
included as they are not relevant given the perspective of this analysis. 
3.7.1 Direct Medical Costs 
The direct medical costs used in this analysis were determined through the analysis of 
data from administrative databases from the province of Ontario for those MCRC patients 
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who received bevacizumab and FOLFIRI as first-line treatment and also from the 
literature. Patient costs were determined using the, OHIP, ODB, NACRS, CIHI-DAD, 
and HCD databases.  The direct medical costs used in this analysis included the cost of 
KRAS testing, cancer clinic visit costs determined using the NACRS, outpatient 
physician service, laboratory, and other health services costs determined from the OHIP 
database. Hospitalization and emergency department visit costs were determined using 
the CIHI-DAD database, drug costs accrued by those patients 65 and older from the ODB 
database, and home care services received using the HCD. 
 Monthly state-specific costs were able to be determined through the use of the NDFP 
database. This database contained information on the line of treatment as well as records 
of every date a patient received treatment. From this data I was able to determine the start 
date of each line of treatment a patient had received. The monthly costs accrued in each 
state were then able to be determined by compiling each date of service/hospitalization 
corresponding to the commencement of each line of treatment. This was conducted for all 
patients and the average of each state dependent monthly cost was estimated. This 
resulted in monthly cost estimates which varied quite differently over time. In order to 
smooth these costs over time, I fit a linear regression model to the monthly total average 
costs. In the BSC state total cost seemed to differ over time. In order to best smooth this 
cost data three separate equations for three separate time periods in which these costs 
seemed to differ were used to smooth the monthly costs. The resultant equation(s) were 
then used to determine the monthly costs that were then inputted into the model. For 
patients who moved into the cancer-free state, monthly costs were determined using the 
average health care utilization costs for  patients in Ontario starting at age 61 to 
correspond with the average age of  patients in the clinical trials used in this analysis 105 .   
3.7.2 Hospitalization Costs 
Hospitalization costs were determined using the CIHI-DAD database. In the 462 patients 
of interest there were a total of 779 hospitalizations, 491 occurred while patients were 
receiving first-line treatment, 166  during second-line, 22 during third-line, and 100 in 
BSC. The average monthly costs can be found in Table 9.2. 
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3.7.3 Physician Costs 
Physician costs were determined using the OHIP database. In the 462 patients of interest 
there were a total of 101,045 OHIP claims. 63,255 of these claims occurred while 
patients were receiving first-line treatment, 23,237 during second-line, 2,856 during 
third-line, and 11,697 in BSC. The average monthly costs can be found in Table 9.2. 
3.7.4 ODB Drug Costs 
ODB drug costs were determined using the ODB database. In the 462 patients of interest 
there were a total of 27,693 ODB claims. 17,477 of these claims occurred while patients 
were receiving first-line treatment, 6,491 during second-line, 600 during third-line, and 
3,125 in BSC. The average monthly costs can be found in Table 9.2. 
3.7.5 Cancer Clinic Costs 
Cancer clinic costs were determined using the NACRS database. In the 462 patients of 
interest there were a total of 10,303 cancer clinic visits. 6,984 of these claims occurred 
while patients were receiving first-line treatment, 2,744 during second-line, 394 during 
third-line, and 181 in BSC. The average monthly costs can be found in Table 9.2.  
3.7.6 Home Care Costs 
Home Care services costs were determined using the ODB database. In the 462 patients 
of interest there were a total of 30,797 home care visits provided. 18,928 of these claims 
occurred while patients were receiving first-line treatment, 7,406 during second-line, 
1,092 during third-line, and 3,371 in BSC. The average monthly costs can be found in 
Table 9.2. 
3.7.7 Drug Costs 
 The cost per milligram administered for patients receiving bevacizumab, cetuximab, and 
panitumumab were able to be obtained from the NDFP database, the London Health 
Science Centre (LHSC) drug formulary intranet, and from literature.  The cost per 
25mg/ml vial of bevacizumab was determined by using data available from the Patented 
Medicine Prices Review Board of Canada (PMPRB) 106. Cost values for cetuximab, 
49 
 
panitumumab, irinotecan, and oxaliplatin were determined from the NDFP database by 
dividing each patients cost per dose by the dose they received of each drug. These values 
were then classified by what drug the patient received and an average value of cost per 
milligram was able to be determined.  The cost of bevacizumab provided by the PMPRB 
was confirmed using this method. The cost per milligram values for fluorouracil and 
leucovorin used in FOLFIRI and FOLFOX regimens were determined using costs 
provided through the London Health Sciences Centre drug formulary intranet (Table 3.5) 
 The average cost per dose for patients who received each drug of interest was found 
using data provided in the NDFP database.  In the clinical trials of interest each treatment 
was delivered in 14 day cycles 13, 34, 38, 41, 90. To determine the monthly cost the 
assumption that a patient would receive each treatment twice a month was made. In 
addition to the cost of the drugs themselves, infusion time costs as well as pharmacy 
preparation costs were included each time a patient received treatment. 
Table 3.5: Drug Costs 
Drug Cost/mg Cost/Dose Cost/Month Source 
Bevacizumab $5.00 $1,879 $3,758 NDFP 
Cetuximab - Initial 
Treatment $3.39 $2,440 $4,880 NDFP 
Cetuximab – All 
other Treatments  $1,620 $3,240 NDFP 
Panitumumab $6.00 $2,697 $5,394 NDFP 
Irinotecan $0.74 $185 $370 NDFP 
Oxaliplatin $10.00 $1,430 $2,860 NDFP 
Fluorouracil + 
Leucovorin  $70 $140 LHSC 
Infusion Time 
 
$213 $426 LHSC 
Pharmacy Prep 
 
$47 $94 LHSC 
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3.7.8 Cost of Adverse Events 
The costs associated with the treatment of grade 3 and grade 4 adverse events were 
captured in this analysis; the management of less severe adverse events would be very 
small to the healthcare payer and thus are negligible from this perspective 73. All the 
adverse events selected to be important at each treatment line was based upon expert 
opinion. The monthly probability of each adverse event occurring were determined from 
the overall complication rates taken from each respective clinical trial (Table 3.6). 
 
Table 3.6: Monthly Probability of Adverse Events 
Treatment Adverse Event Monthly Probability Source 
Bevacizumab + FOLFIRI Hypertension 0.0012 65
 
 
Wound-healing complication 0.0005 65
 
 
GI perforation 0.0005 65
 
 
Diahorrea 0.0089 65
 
 
Pain 0.0040 65
 
Cetuximab + FOLFIRI Neutropenia 0.0151 13 
 
Leukopenia 0.0034 13
 
 
Diarrhea 0.0074 13
 
 
Vomiting 0.0017 13
 
 
Rash 0.0072 13
 
 
Infusion-related reactions 0.0011 13
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Panitumumab + FOLFIRI Neutropenia 0.0404 38
 
 
Skin toxicity 0.0332 38
 
 
Diarrhea 0.0149 38
 
 
Hypokalemia 0.0080 38
 
 
Infusion related 0.0080 38
 
FOLFOX Hypertension 0.0045 12
 
Treatment Adverse Event Monthly Probability Source 
 
Bleeding 0.0010 12
 
 
Vomiting 0.0081 12
 
 
Neuropathy (pain) 0.0238 12
 
FOLFOX + Bevacizumab Hypertension 0.0023 12
 
 
Bleeding 0.0012 12
 
 
Vomiting 0.0038 12
 
 
Neuropathy (pain) 0.0063 12
 
Panitumumab Monotherapy Rash/Skin Toxicity 0.0053 41
 
 
Vomiting 0.0015 41
 
 
Diarrhea 0.0009 41
 
 
Cost estimation of treating these adverse events was determined from a search of the 
OHIP database for the fee codes associated with the treatment of each adverse event. For 
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those adverse events which did not have directly associated OHIP fee codes, costs were 
obtained from literature review, while the cost for hypokalemia and thromboembolism 
expert opinion 107, 108. The cost of treating GI hemorrhage was used for bleeding events, 
the cost of treating non-neutropenic infection was used as the cost of treating both 
neutropenia and leucopenia, infusion-related reaction cost was determined by using the 
cost of treating poisoning by drugs, medications, and biological substances plus the 
average cost of an emergency room visit, while the average cost of an emergency 
department visit was used for the cost of wound complication. The cost of hypokalemia 
was determined using cost data from the LHSC drug formulary along with clinical 
guidelines for the cost of EGFR-induced hypomagnesiad 107. The monthly cost of treating 
adverse events for each treatment line was determined by finding the sum total of each 
adverse events monthly probability by the cost of treating each event (Table 3.7). 
Table 3.7: Cost of Treating Adverse Events 
Adverse Event Cost per 
event Source 
Hypertension $42.63 OHIP Fee Codes 
GI Hemorrhage $3,388.33 CIHI patient cost 
estimator 
Pain $28.75 73
 
Diarrhea $46.36 OHIP Fee Codes 
Non-neutropenic infection 
(Neutropenia/Leukopenia) $2,491.30 73 
Rash/Skin toxicity $37.10 OHIP Fee Codes 
Hypokalemia $6.23 LHSC drug formulary 
Infusion related reaction $6,613.72 109
 
ER Visit ( Wound Healing Complication) $153.59 110
 
Vomiting $72.57 OHIP Fee Codes 
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Thromboembolism $1.75 LHSC drug formulary 
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Table 3.8: Model Parameters and Sources 
 
Variable Base Case Value Duration 
Ranges Tested 
in Sensitivity 
Probability 
Distribution Reference 
 
 
   
Lognormal (µ,σ) 
 Treatment 
Costs Bevacizumab $3,758 
Treatment 
Course ±20% 8.01, 0.67 NDFP 
 
Cetuximab- 
Initial Dose $4,880 
Treatment 
Course ±20% 8.27,0.67 NDFP 
 
Cetuximab - 
Every Dose 
After 
$3,240 Treatment Course ±20% 7.86,0.67 NDFP 
 
Panitumumab $5,394 Treatment Course ±20% 8.37,0.67 NDFP 
 
FOLFIRI $440 Treatment Course ±20% 5.86,0.67 NDFP, LHSC 
 
FOLFOX $3230 Treatment Course ±20% 7.86, 0.67 NDFP. LHSC 
 
Infusion Time $426.00 Treatment Course ±20% 5.83,0.47 LHSC 
 
Pharmacy 
Preparation $94.00 
Treatment 
Course ±20% 4.32,0.48 LHSC 
       Total First-Line 
Costs  
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
OHIP/ODB/HC
D/NACRS/DAD 
 
      Cancer Free 
Costs  $359.40 First 48 Months ±20% 5.66, 0.67 CIHI 
  
$543.15 Following  Months ±20% 6.07, 0.67 CIHI 
       Total Second-
Line Costs  
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
OHIP/ODB/HC
D/NACRS/DAD 
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Variable Base Case Value Duration 
Ranges Tested 
in Sensitivity 
Probability 
Distribution Reference 
Total Third-
Line Costs  
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
OHIP/ODB/HC
D/NACRS/DAD 
       Total Best-
Supportive 
Care Costs  
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
OHIP/ODB/HC
D/NACRS/DAD 
       
Adverse Event  
Costs 
Bevacizumab + 
FOLFIRI $2.24 
Treatment 
Course ±20% 0.22, 0.76 
65
 
 
Cetuximab + 
FOLFIRI $53.87 
Treatment 
Course ±20% 3.81, 0.42 
13
 
 
Panitumumab + 
FOLFIRI $155.27 
Treatment 
Course ±20% 4.82, 0.47 
38
 
 
FOLFOX $4.86 Treatment Course ±20% 1.32, 0.59 
90
 
 
FOLFOX + 
Bevacizumab $4.74 
Treatment 
Course ±20% 1.32, 0.48 
90
 
 
Panitumumab $1.50 Treatment Course ±20% 0.18, 0.67 
41
 
       
     
Beta (α,β) 
 
Health State 
Utilities 
Bevacizumab + 
FOLFIRI 0.77 
Treatment 
Course ±20% 77, 100 
99
 
 
Cetuximab + 
FOLFIRI 0.77 
Treatment 
Course ±20% 77, 100 
101
 
 
Panitumumab 
+FOLFIRI 0.778 
Treatment 
Course ±20% 778, 1000 
97
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Variable Base Case Value Duration 
Ranges Tested 
in Sensitivity 
Probability 
Distribution Reference 
 
FOLFOX 0.756 
  
756, 1000 97
 
 
FOLFOX + 
Bevacizumab 0.756 
Treatment 
Course ±20% 756, 1000 
97
 
 
Panitumumab 0.72 
  
72, 100 98
 
 
Best-Supportive 
Care 0.68 
Treatment 
Course ±20% 68, 100 
98
 
 
Cancer Free 0.84 Treatment Course ±20% 84, 100 
100
 
 
Dead 0 
    
     
Beta (α,β) 
 Transition 
Probabilities 
Bevacizumab + 
FOLFIRI PFS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month NDFP 
 
Cetuximab + 
FOLFIRI PFS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
13
 
 
Panitumumab + 
FOLFIRI PFS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
38
 
 
FOLFOX PFS Varying By Month 
Treatment 
Course ±20% 
Varying By 
Month 
90
 
 
FOLFOX + 
Bevacizumab 
PFS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
90
 
 
Panitumumab 
Monotherapy 
PFS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
41
 
 
Best-Supportive 
Care OS 
Varying By 
Month 
Treatment 
Course ±20% 
Varying By 
Month 
34
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Variable Base Case Value Duration 
Ranges Tested 
in Sensitivity 
Probability 
Distribution Reference 
 
Bevacizumab to 
Cancer Free 0.001536953 
Treatment 
Course ±20% 15, 10000 
65
 
 
Cetuximab to 
Cancer Free 0.003423096 
Treatment 
Course ±20% 34, 10000 
13
 
 
Panitumumab to 
Cancer Free 0.008284798 
Treatment 
Course ±20% 83, 10000 
13
 
 
Cancer 
Recurrence First 60 Months 0.012392865 ±20% 124, 10000 
89
 
  
Following 
Months 0.003733782 ±20% 37, 10000 
89
 
 
Background 
Mortality Rate 
Varying By 
Month Lifetime   
91
 
Discount Rate 
  
0.5 0-0.5% 
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3.8 Discounting 
All costs and QALYS were discounted at an annual rate of 5% to be consistent with 
standard practice of economic evaluations in Canada 111, 112. The discounting of QALYs 
is a controversial topic in cost-effectiveness analyses as there are differing views as to 
whether individuals value QALY equally over time 113. Although the discounting of 
QALYS goes against the theory of welfare economics which implies that individuals 
weigh health benefits by some measure of willingness to pay value, the US Panel on 
Cost-Effectiveness in Health and Medicine recommends the discounting of QALYS as to 
introduce a standard practice 113, 114.  
3.9 Sensitivity Analyses 
Both deterministic and probabilistic sensitivity analyses were carried out in TreeAge 
(TreeAge Software Inc., Williamstown, MA) to determine the robustness of the base-case 
result as well as to address any potential uncertainty in key model parameters. One-way 
deterministic sensitivity analyses were carried out in a +/- 20% range of each base case 
value for all costs, transition probabilities, and health utilities. Probabilistic sensitivity 
analysis was carried out in 10,000 Monte Carlo simulations where monthly transition 
probabilities, state dependent probabilities, and utility values were estimated using beta 
distributions, while costs were determined using log-normal distributions (Table 3.8). 
3.10 Software 
The decision analysis model was built using TreeAge Pro Suite 2009™ (TreeAge 
Software, Williamstown, MA, USA). All descriptive data analysis and survival data 
analysis were conducted using SAS software™ (SAS Institute Inc., Cary, NC, USA). 
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4 Chapter 4: Results 
4.1 Cohort Data Analysis 
4.1.1 Estimated Average Cost of Disease 
The total cost to the payer over for patients treated with first-line bevacizumab plus 
FOLFIRI was found on average to be $121,750 over the course of their disease. The 
average total costs for patients receiving each potential treatment course can be found in 
Table 4.1 
 
Table 4.1: The Average Cost of Treatment for Patients Receiving First-Line 
Bevacizumab Plus FOLFIRI. 
 
Treatment 
Courses 
Received N Clinic 
Home 
care Hospital ODB OHIP NDFP Total 
1 237 $16,405 $4,567 $22,872 $8,099 $14,707 $39,069 $105,720 
12 49 $21,283 $5,975 $21,251 $9,742 $14,194 $49,716 $122,162 
13 2 $36,541 $1,425 $14,590 $0 $16,351 $94,621 $163,528 
14 145 $17,305 $434 $24,996 $8,893 $15,262 $37,544 $104,435 
15 87 $8,957 $4,404 $34,552 $5,116 $9,694 $18,404 $81,128 
123 13 $24,583 $4,672 $17,091 $4,291 $12,410 $92,353 $155,400 
124 49 $25,216 $8,262 $23,217 $12,705 $14,575 $52,032 $136,008 
125 50 $16,376 $5,786 $36,490 $6,960 $9,840 $29,642 $105,094 
134 36 $22,963 $5,122 $30,435 $7,931 $14,389 $46,371 $127,211 
135 10 $21,250 $5,969 $42,075 $7,419 $12,562 $41,173 $130,449 
145 259 $12,568 $4,900 $36,660 $6,281 $12,358 $20,728 $93,495 
1234 18 $22,909 $4,473 $21,489 $10,050 $13,597 $65,045 $137,564 
1235 15 $19,509 $4,900 $20,824 $12,571 $7,848 $46,657 $112,308 
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Treatment 
Courses 
Received N Clinic 
Home 
care Hospital ODB OHIP NDFP Total 
1245 178 $21,302 $6,066 $26,215 $7,705 $12,056 $39,663 $113,006 
12345 68 $26,371 $7,154 $25,969 $8,652 $13,623 $56,961 $138,729 
*Note that the numbers in column 1 represent the following sequence of events: 1= First-
line bevacizumab + FOLFIRI, 2= Second-line FOLFOX, 3= Third-line Panitumumab, 
4=Best Supportive Care, and 5=Death 
 
4.1.2 Monthly Costs 
 Monthly state-specific costs were determined from the 1216 patients of interest. The 
total monthly costs found from the patient level data and the smoothed costs used in the 
linear regression can be are reported in Table 9.1. The component costs from each 
respective database are presented in Table 9.2 . For patients who received first-line 
treatment the average monthly  cancer clinic costs was $479.19, home care cost was 
$134.47, hospital cost was $523.50,  ODB drug cost was $223.86, and  outpatient 
physician cost  was $270.54.  The average monthly total healthcare cost over the course 
of first-line treatment was $1660.86. A graph of the total monthly first-line costs can is 
presented in Figure 4.1 . 
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Figure 4.1: Total Monthly First-Line Costs 
 
For patients who received second-line treatment the average monthly clinic cost was 
$483.65, home care cost was $142.54, hospital cost was $391.92, ODB drug cost was 
$227.00, and outpatient physician costs were $238.62.  The average monthly total 
healthcare cost over the course of second-line treatment was $1483.73. A graph of the 
total monthly second- line costs is depicted in Figure 4.2. 
Figure 4.2: Total Monthly Second-Line Costs 
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For patients who received third-line treatment the average monthly clinic cost was 
$441.29, home care cost was $161.02, hospital cost was $403.23, ODB drug cost was 
$184.31, and outpatient physician costs were $284.94.  The average monthly total 
healthcare expenditure over the course of third-line treatment was $1474.78. A graph of 
the total monthly third-line costs is presented in Figure 4.3. 
 
Figure 4.3: Total Monthly Third-line Costs 
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$104.98, and outpatient physician costs were $197.36.  The average monthly total 
healthcare expenditure over the course of best-supportive care was $775.23. A graph of 
the monthly BSC costs can be found in Figure 4.4-4.6. 
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Figure 4.4: Total Monthly Costs in Months 1 to 7 of Best Supportive Care 
 
 
Figure 4.5: Total Monthly Costs in Months 8 to 15 of Best Supportive Care 
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Figure 4.6: Total Monthly Costs in Months 16 to 22 of Best Supportive Care 
 
4.1.3 Survival Analyses 
The progression-free survival estimate for patients receiving first-line bevacizumab and 
FOLFIRI was determined from the analysis of the patient-level data. In this cohort the 
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Figure 4.7: Progression-Free Survival of the 1216 Patients Receiving First-Line 
Bevacizumab + FOLFIRI 
 
 
Parametric regression was used to fit Weibull distributions to the PFS and OS curves 
determined from the patient level data and respective clinical trials. The estimated 
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Weibull distributions were used to determine the monthly transition probabilities as they 
facilitated the hazard rate of progressing to differ over time. Graphs comparing the in-
trial and Weibull-estimated survival curves estimates were then constructed (Figure 4.8-
4.13). 
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Table 4.2: Shape and Scale Parameters Determined from Weibull Regression 
Treatment Weibull Shape (β) Weibull Scale (σ) 
Bevacizumab + 
FOLFIRI 1.3426 16.4469 
Cetuximab + FOLFIRI 1.5963 16.4864 
Panitumumab + 
FOLFIRI 1.563 15.8595 
Third Line 
Panitumumab 1.4249 22.6985 
Best Supportive Care 1.2827 10.8512 
 
Figure 4.8: Comparison of Observed and Weibull Fitted PFS Estimates for Patients 
Receiving First-Line Bevacizumab + FOLFIRI 
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Figure 4.9: Comparison of Reported Clinical Trial and Weibull Fitted PFS 
Estimates for Patients Receiving First-Line Cetuximab + FOLFIRI 
 
Figure 4.10: Comparison of PFS Estimates for Patients Receiving First-Line 
Panitumumab + FOLFIRI 
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Figure 4.11: Comparison of PFS Estimates for Patients Receiving Second-Line 
FOLFOX
 
Figure 4.12: Comparison of PFS Estimates for Patients Receiving Third-Line 
Panitumumab 
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Figure 4.13: Comparison of OS Estimates for Patients Receiving Best-Supportive 
Care 
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survival curves generated by the patient-level data and the clinical trial data in 
parameterized models are presented in Figure 4.14. 
Figure 4.14: Comparison of the Overall Survival Curves Generated When Model 
M1 Was Parameterized With Patient-Level and Randomized Clinical Trial Data. 
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Figure 4.15: The Results Displayed on the Cost-Effectiveness Plane 
 
*Note B= Bevacizumab + FOLFIRI, C= Cetuximab + FOLFIRI, P=Panitumumab + FOLFIRI 
 
Table 4.3: Results of the Base Case Analysis 
Treatment Cost QALY ICER 
Bevacizumab + 
FOLFIRI $150,572.08 1.749  
Cetuximab + 
FOLFIRI $153,730.63 1.741 Dominated 
Panitumumab + 
FOLFIRI $173,930.64 1.716 Dominated 
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bevacizumab plus FOLFIRI were decreased (i.e. treatment was more effective), treatment 
with bevacizumab and FOLFIRI became more costly and more effective than treatment 
with cetuximab plus FOLFIRI. Decreases of 10% and 20% resulted in ICER values of 
$39,539/QALY and 64,343/QALY respectively when compared to treatment with 
cetuximab and FOLFIRI (Figure 4.16).  Ten and twenty percent increases in the 
transition probabilities (treatment being less effective) of treatment with bevacizumab 
and FOLFIRI resulted in treatment with cetuximab and FOLFIRI being the most effective 
treatment strategy. However, in these scenarios the ICER values of treatment with 
cetuximab plus FOLFIRI were both found to be greater than $100,000/QALY when 
compared to bevacizumab and FOLFIRI (Figure 4.16).  
Figure 4.16: The Results of the Deterministic Sensitivity Analysis on the 
Effectiveness of Treatment with First-Line Bevacizumab Plus FOLFIRI 
 
*Note: There are no ICER values for treatment the ICER generated for bevacizumab plus FOLFIRI versus 
cetuximab plus FOLFIRI for transition probability multipliers greater than 0.9 as past this point treatment 
bevacizumab plus FOLFIRI is the dominant treatment option. 
* Note: There are no ICER values for treatment the ICER generated for cetuximab plus FOLFIRI versus 
cetuximab plus FOLFIRI for transition probability multipliers less than 1.1 as before this point treatment 
bevacizumab plus FOLFIRI is the dominant treatment option. 
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were decreased, treatment with cetuximab and FOLFIRI became more costly and more 
effective than treatment with first-line bevacizumab plus FOLFIRI, however this resulted 
in ICER values of greater than $100,000/QALY. A decrease in the monthly transition 
probabilities of 10% resulted in an incremental gain of 0.048 QALYS at an incremental 
cost of $7,797 resulting in an ICER value of $164,127/QALY while a decrease of 20% 
resulted in an incremental gain of 0.11 QALYS at an incremental cost of $13,200 for an 
ICER value $115,449/QALY (Figure 4.17). 
Figure 4.17: The Results of the Deterministic Sensitivity Analysis on the 
Effectiveness of Treatment with First-Line Cetuximab Plus FOLFIRI 
 
*Note: There are no ICER values for treatment the ICER generated for bevacizumab plus FOLFIRI versus 
cetuximab plus FOLFIRI for transition probability multipliers less than 1.1 as before this point treatment 
bevacizumab plus FOLFIRI is the dominant treatment option. 
* Note: There are no ICER values for treatment the ICER generated for cetuximab plus FOLFIRI versus 
cetuximab plus FOLFIRI for transition probability multipliers greater than 0.9 as beyond this point 
treatment bevacizumab plus FOLFIRI is the dominant treatment option. 
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The cost of cetuximab had dramatic effects on the final ICER values. As the cost of 
cetuximab increased treatment with bevacizumab plus FOLFIRI retained its dominance, 
however as this cost of cetuximab decreased it became the most cost-effective option, 
becoming less costly than treatment with bevacizumab plus FOLFIRI. When the cost of 
cetuximab was decreased by 10% it resulted in bevacizumab and FOLFIRI having an 
ICER value of $144,204/QALY when compared to treatment with cetuximab and 
FOLFIRI. This ICER value then increased to $652,855/QALY when the cost of 
cetuximab decreased 20% (Figure 4.18).  
Figure 4.18: The Results of the Deterministic Sensitivity Analysis on the Cost of 
Cetuximab. 
 
*Note: There are no ICER values for treatment the ICER generated for bevacizumab plus FOLFIRI versus 
cetuximab plus FOLFIRI for transition probability multipliers greater than 0.9 as past this point treatment 
bevacizumab plus FOLFIRI is the dominant treatment option. 
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incremental gain of 0.082 QALYS resulting in an ICER $38,677/QALY.  When this 
value was decreased by 20% the incremental effect of cetuximab and FOLFIRI increased 
to 0.172 QALY, resulting in the ICER value dropping to $18,373/QALY (Figure 4.19). 
Increases in the utility value of patients receiving cetuximab plus FOLFIRI had a similar 
result, with an increase in utility by 10% resulting in an incremental gain of 0.079 QALY 
resulting in and ICER of $40,194/QALY, and an increase of 20% resulting in an 
incremental gain of 0.166 QALY and an ICER of $19.037/QALY (Figure 4.20). 
Figure 4.19: The Results of the Deterministic Sensitivity Analysis on the Utility of 
First-Line Bevacizumab Plus FOLFIRI. 
 
*Note: There are no ICER values for treatment the ICER generated for cetuximab plus FOLFIRI versus 
bevacizumab plus FOLFIRI for transition probability multipliers greater than 0.9 as past this point 
treatment bevacizumab plus FOLFIRI is the dominant treatment option. 
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Figure 4.20: The Results of the Deterministic Sensitivity Analysis on the Utility of 
First-Line Cetuximab Plus FOLFIRI. 
 
*Note: There are no ICER values for treatment the ICER generated for cetuximab plus FOLFIRI versus 
bevacizumab plus FOLFIRI for transition probability multipliers less than 1.1 as before this point treatment 
bevacizumab plus FOLFIRI is the dominant treatment option. 
 
I conducted two-way sensitivity analyses on the effectiveness and the monthly cost of 
cetuximab and panitumumab. Treatment consisting of cetuximab plus FOLFIRI became 
the dominant treatment option when the monthly transition probabilities were decreased 
by 5% and the monthly cost was reduced by 15%. The ICER for treatment with 
cetuximab plus FOLFIRI fell below the $100,000/QALY willingness-to-pay threshold 
when the monthly transition probabilities were decreased by 5% and monthly cost were 
reduced by 10% (Figure 4.21). Treatment consisting of panitumumab plus FOLFIRI 
became the dominant treatment option when the monthly transition probabilities were 
decreased by 10% and monthly cost of panitumumab was decreased by 50%. The ICER 
value fell below $100,000/QALY when the monthly transition probabilities were 
decreased by 10% and costs were decreased by 45% (Figure 4.22). 
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Figure 4.21: Results of Two-Way Sensitivity Analyses on the Effectiveness of First-
Line Cetuximab plus FOLFIRI and the Monthly Cost of Cetuximab 
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Figure 4.22: Results of Two-Way Sensitivity Analyses on the Effectiveness of First-
Line Panitumumab plus FOLFIRI and the Monthly Cost of Panitumumab 
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Table 4.4: Results of One-Way Deterministic Sensitivity Analyses. 
Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
Effectiveness  of 1st 
Line Bevacizumab+ 
FOLFIRI 
0.8 Cetuximab + FOLFIRI $153,731 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $164,288 $10,557 1.905 0.164 $64,342 
 
       
 
0.9 Cetuximab + FOLFIRI $153,731 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $156,864 $3,133 1.820 0.079 $39,539 
 
       
 
1.1 Bevacizumab + FOLFIRI $145,151  1.689   
 
 
Cetuximab + FOLFIRI $153,731 $8,579 1.741 0.051 $167,676 
 
       
 
1.2 Bevacizumab + FOLFIRI $140,418  1.638   
 
 
Cetuximab + FOLFIRI $153,731 $13,313 1.741 0.103 $129,778 
 
       
Effectiveness  of 1st 
Line Cetuximab+ 
FOLFIRI 
0.8 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $163,772 $13,200 1.864 0.114 $115,448 
 
       
 
0.9 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $158,368 $7,796 1.797 0.048 $164,127 
 
       
 
1.1 Cetuximab + FOLFIRI $149,688 
 
1.692 
  
 
 
Bevacizumab + 
FOLFIRI $150,572 $884 1.749 0.057 $15,553 
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Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
 
1.2 Cetuximab + FOLFIRI $146,120 
 
1.651 
  
 
 
Bevacizumab + 
FOLFIRI $150,572 $4,452 1.749 0.099 $45,160 
 
       
 
       
Effectiveness  of 1st 
Line Panitumumab+ 
FOLFIRI 
0.8 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Panitumumab + 
FOLFIRI $187,931 $37,359 1.836 0.087 $428,587 
 
       
 
0.9 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Panitumumab + 
FOLFIRI $180,385 $29,813 1.771 0.022 $1,375,996 
 
       
Effectiveness of 2nd 
Line FOLFOX 0.8 Cetuximab + FOLFIRI $153,731  1.741   
 
 
Bevacizumab + 
FOLFIRI $154,036 $305 1.791 0.051 $6,037 
 
       
 
1.1 Bevacizumab + FOLFIRI $149,258  1.734   
 
 
Cetuximab + FOLFIRI $153,731 $4,473 1.741 0.007 $654,587 
 
       
 
1.2 Bevacizumab + FOLFIRI $148,132  1.721   
 
 
Cetuximab + FOLFIRI $153,731 $5,598 1.741 0.020 $283,460 
 
       
Effectiveness of 2nd 
Line FOLFOX + 
Bevacizumab 
0.8 Bevacizumab + FOLFIRI $150,572  1.749   
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Cetuximab + FOLFIRI $160,697 $10,125 1.791 0.042 $242,027 
 
       
Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
 
0.9 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $156,857 $6,285 1.763 0.014 $454,319 
 
       
 
1.2 Cetuximab + FOLFIRI $148,905 
 
1.706 
  
 
 
Bevacizumab + 
FOLFIRI $150,572 $1,667 1.749 0.043 $38,850 
Percentage who move 
to 2nd Line after 1st 
Line 
0.8 Cetuximab + FOLFIRI $155,130 
 
1.781 
  
 
 
Bevacizumab + 
FOLFIRI $157,595 $2,465 1.833 0.051 $48,012 
 
       
 
1.1 Bevacizumab + FOLFIRI $147,540  1.714   
 
 
Cetuximab + FOLFIRI $153,018 $5,478 1.722 0.008 $650,859 
 
       
 
1.2 Bevacizumab + FOLFIRI $144,765  1.682   
 
 
Cetuximab + FOLFIRI $152,306 $7,541 1.706 0.023 $324,338 
 
       
Percentage who move 
to BSC after 1st Line 0.8 
Bevacizumab + 
FOLFIRI $155,356  1.794   
 
 
Cetuximab + FOLFIRI $161,458 $6,103 1.811 0.017 $353,768 
 
       
Percentage who move 
to BSC after 2nd 
Line 
0.8 Cetuximab + FOLFIRI $153,731 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $154,442 $711 1.777 0.036 $19,710 
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Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
 
1.1 Bevacizumab + FOLFIRI $148,964  1.738   
 
 
Cetuximab + FOLFIRI $153,731 $4,767 1.741 0.003 $1,787,453 
 
       
 
1.2 Bevacizumab + FOLFIRI $147,525  1.728   
 
 
Cetuximab + FOLFIRI $153,731 $6,205 1.741 0.013 $486,681 
 
       
Cost of Bevacizumab 1.1 Cetuximab + FOLFIRI $155,608 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $155,859 $251 1.749 0.009 $28,980 
 
       
 
1.2 Cetuximab + FOLFIRI $157,485 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $161,146 $3,661 1.749 0.009 $422,408 
 
       
Cost of Cetuximab 0.8 Cetuximab + FOLFIRI $144,914 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $150,572 $5,658 1.749 0.009 $652,855 
 
       
 
0.9 Cetuximab + FOLFIRI $149,322 
 
1.741 
  
 
 
Bevacizumab + 
FOLFIRI $150,572 $1,250 1.749 0.009 $144,204 
 
       
Utility 1st Line 
Bevacizumab + 
FOLFIRI 
0.8 Bevacizumab + FOLFIRI $150,572  1.569   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.741 0.172 $18,373 
 
       
 
0.9 Bevacizumab + FOLFIRI $150,572  1.659   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.741 0.082 $38,676 
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Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
Utility 1st Line 
Cetuximab + 
FOLFIRI 
1.1 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.828 0.079 $40,194 
 
       
 
1.2 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.915 0.166 $19,037 
 
       
Utility 1st Line 
Panitumumab + 
FOLFIRI 
1.1 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Panitumumab + 
FOLFIRI $173,931 $23,359 1.802 0.052 $445,632 
 
       
 
1.2 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Panitumumab + 
FOLFIRI $173,931 $23,359 1.888 0.138 $168,755 
 
       
Utility of 2nd Line 
FOLFOX 0.8 
Bevacizumab + 
FOLFIRI $150,572  1.692   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.741 0.049 $65,013 
 
       
 
0.9 Bevacizumab + FOLFIRI $150,572  1.721   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.741 0.020 $157,928 
 
       
Utility of 2nd Line 
FOLFOX + 
Bevacizumab 
1.1 Bevacizumab + FOLFIRI $150,572  1.749   
 
 
Cetuximab + FOLFIRI $153,731 $3,159 1.772 0.023 $140,380 
 
       
84 
 
Variable Value Multiplier Strategy Cost Incr. Cost 
Effectiveness 
(QALY) 
Incr. 
Effectiveness 
(QALY) 
ICER 
($/QALY) 
 
1.2 Bevacizumab + FOLFIRI $150,572  1.749   
  
Cetuximab + FOLFIRI $153,731 $3,159 1.803 0.054 $58,764 
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4.5 Probabilistic Sensitivity Analysis 
In the probabilistic sensitivity analyses we sampled simultaneously from the distributions 
inputted for the monthly transition probabilities, state-dependent probabilities, utility 
values, and costs.  From these simulations we were able to construct the cost-
effectiveness (CE) scatter plot which plots the incremental cost and incremental 
effectiveness each simulation being compared. The CE graph for comparing patients 
receiving first-line cetuximab plus FOLFIRI and bevacizumab plus FOLFIRI can be 
found in Figure 4.23.  Treatment consisting of cetuximab plus FOLFIRI was dominant to 
treatment with bevacizumab and FOLFIRI in 0.4% of the cases, all of which landed in 
quadrant I indicating increased cost and increased effect. At a willingness-to-pay (WTP) 
value of $100,000/QALY 100% of these simulations lie above the threshold. This 
number did not change when the WTP was increased to $200,000/QALY. Treatment with 
cetuximab and FOLFIRI was found to be inferior in 30.1% of the simulations, while 
69.1% of simulations landed in quadrant III, all of which landed above the WTP 
threshold (Figure 4.23). From the cost-effectiveness acceptability curve constructed from 
the data, it was found that at a WTP threshold of 100,000/QALY the probability that 
treatment with cetuximab plus FOLFIRI would be cost effective when compared to first-
line treatment with bevacizumab plus FOLFIRI was 0.008%. This value remained 
unchanged when the WTP threshold was increased to $200,000/QALY (Figure 4.24). 
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Figure 4.23: Incremental Cost-Effectiveness Scatter Plot Comparing Cetuximab + 
FOLFIRI to Bevacizumab + FOLFIRI 
  
 
Figure 4.24: Cost-Effectiveness Acceptability Curves for First-Line Cetuximab + 
FOLFIRI and Panitumumab + FOLFIRI 
 
 
$100,000/QALY
$200,000/QALY
-400000
-300000
-200000
-100000
0
100000
200000
300000
400000
500000
-1.5 -1 -0.5 0 0.5 1 1.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 50000 100000 150000 200000 250000 300000
P
ro
b
a
b
il
it
y
 o
f 
b
e
in
g
 c
o
st
-e
ff
e
ct
iv
e
Willingness-To-Pay
Panitumumab + FOLFIRI
Cetuximab + FOLFIRI
87 
 
In the ICE scatter plot comparing treatment consisting of panitumumab plus FOLFIRI 
was dominant to treatment with bevacizumab and FOLFIRI in 0.2% of the cases, with 
half of these simulations landed in quadrant I indicating increased cost and increased 
effect. Treatment with panitumumab and FOLFIRI was found to be inferior in 47.1% of 
the simulations, while 52.6% of simulations landed in quadrant III, none of which landed 
below the WTP threshold (Figure 4.25). These values remained unchanged when the 
WTP was increased to $200,000/QALY. From the cost-effectiveness acceptability curve 
constructed from the data, it was found that at a WTP threshold of 100,000/QALY the 
probability that treatment with panitumumab plus FOLFIRI would be cost effective when 
compared to first-line treatment with bevacizumab plus FOLFIRI was 0.03%, a value 
remained unchanged when the WTP threshold was increased to $200,000/QALY (Figure 
4.24). 
Figure 4.25: Incremental Cost-Effectiveness Scatter Plot Comparing Panitumumab 
+ FOLFIRI to Bevacizumab + FOLFIRI 
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Chapter 5 
5 Discussion, Limitations, and Strengths 
5.1 Summary 
I developed a decision analytic model composed of three Markov models, each one 
capturing the clinical course of patients diagnosed with metastatic colorectal cancer 
beginning when they first start treatment until their death. This model was conceptualized 
based upon the common clinical practice in the province of Ontario for patients receiving 
first line treatment consisting of either the current standard of care of bevacizumab with 
FOLFIRI, or alternate treatment consisting of either cetuximab or panitumumab in 
combination with the FOLFIRI chemotherapy regimen. Using this model I was able to 
investigate the cost-effectiveness of combination treatment consisting of panitumumab or 
cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI for KRAS wild-type 
metastatic colorectal cancer patients from the perspective of the Ontario healthcare payer. 
 In the base scenario combination treatment consisting of bevacizumab plus FOLFIRI 
was found to dominate both other treatment options. Treatment with cetuximab plus 
FOLFIRI was found to be very similar to treatment with bevacizumab plus FOLFIRI in 
terms of both cost and effect, differing in cost by less than $3,200 and a difference of 
only 0.008 QALY. Treatment with panitumumab plus FOLFIRI was found to be both 
more costly and less effective when compared to treatment with both bevacizumab plus 
FOLFIRI, and treatment with cetuximab plus FOLFIRI. From this result we can conclude 
that the current standard of care in Ontario of the use of bevacizumab plus FOLFIRI for 
first-line treatment of patients with metastatic colorectal cancer is the most cost-effective 
treatment option for these patients.   
After completing one-way deterministic sensitivity analyses these ICER values were 
determined to be sensitive towards the each first-line treatment’s monthly transition 
probabilities (i.e treatment effectiveness), the acquisition cost of bevacizumab and 
cetuximab, and the health utility values associated with the first-line treatments.  The 
results of probabilistic sensitivity analysis which tested for uncertainty in all model 
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parameters found that the use of cetuximab plus FOLFIRI was a superior treatment 
option to bevacizumab plus FOLFIRI less than 0.4% of the time, and of these cases all of 
them fell above the willingness-to-pay threshold of $100,000/QALY. Probabilistic 
sensitivity analysis also showed that treatment with panitumumab plus FOLFIRI was 
almost always inferior treatment with bevacizumab and FOLFIRI with treatment 
consisting of panitumumab found to be superior in only 0.2% of simulations. 
5.2 Discussion 
From this analysis we can conclude that for KRAS wild-type patients with metastatic 
colorectal cancer the current standard of care consisting of combination treatment with 
bevacizumab plus FOLFIRI  in the first-line represents the most-cost effective treatment 
option when compared to the other monoclonal antibody plus chemotherapy regimens 
which are currently available. In Ontario both cetuximab and panitumumab are only 
prescribed for patients who are found to be KRAS-WT only. The use of cetuximab as a 
monotherapy is currently used in second-line treatment and in third-line settings in 
combination with irinotecan while panitumumab monotherapy is currently used in third 
line treatment 58. From our analysis we can conclude that in terms of value-for-money 
these treatment guidelines represent the most cost-effective use of these treatments. 
 Treatment consisting of bevacizumab and FOLFIRI was found to dominate treatment 
consisting of panitumumab and FOLFIR in the base case scenario. Over the course of 
undertaking deterministic sensitivity analysis, certain situations arose where treatment 
with panitumumab plus FOLFIRI no longer became dominated, however in each of these 
scenarios the resultant ICERs fell well above the $100,000/QALY threshold which is 
indicative of “weak evidence for adoption” in Canada 106. Based on the analysis I can 
conclude that given that this treatment should not be considered for use in the first line.  
 In the base case analysis treatment with cetuximab and FOLFIRI was found to be more 
costly and less effective than treatment with bevacizumab, however both the cost and 
effect of treatment with cetuximab plus FOLFIRI only differed slightly from that of 
treatment with bevacizumab plus FOLFIRI. The difference in cost of the two treatments 
was only $3,159 with the difference in effect being only 0.008 QALY. From these results 
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it looks as though treatment with cetuximab and FOLFIRI is almost equivalent to 
treatment with bevacizumab and FOLFIRI. In deterministic sensitivity analysis there 
were scenarios where treatment consisting of cetuximab plus FOLFIRI was the most 
cost-effective treatment option, or when this combination treatment was found to have 
ICER values under the $100,000/QALY willingness-to-pay threshold. This was the case 
when either the utility of patients receiving bevacizumab plus FOLFIRI decreased or 
when the utility of patients receiving cetuximab plus FOLFIRI increased. Under these 
scenarios treatment with cetuximab and FOLFIRI was found to have ICER values 
ranging between $18,373/QALY to $40,194/QALY. 
 The results of this analysis differ from the results found in two previous cost-
effectiveness analyses that looked at the use of cetuximab and FOLFIRI compared to 
bevacizumab and FOLFOX 76, 77. In the study by Asseburg et al, cetuximab and FOLFIRI 
was found to have an ICER €15,020/LY, while Samyshkin et al found a value of 
£28,626/QALY.  One possible reason for the difference in these estimates is due to the 
fact that these analyses looked at bevacizumab with FOLFOX, a regimen which is much 
more expensive than FOLFIRI due to the increased cost of oxaliplatin, as well as 
differences in the utility values used. The use of FOLFOX in these analyses would have 
resulted in an increased cost of the total combination treatment, thus resulting in a smaller 
incremental cost of the use of cetuximab and FOLFIRI and thus lower ICER values. The 
differences in this analysis may be due to the cause of different modeling assumptions, 
model structure and extrapolation methods, and data sources.  
 
5.3 Limitations 
We recognize that there are several limitations in this study. Firstly, the same quality-of-
life value was used for both patients receiving first-line cetuximab plus FOLFIRI and 
bevacizumab and FOLFIRI.  A literature review resulted in these values, however given 
the inherent differences of bevacizumab and cetuximab it is fair to assume that the utility 
values for patients receiving these treatments may not be the same in reality. Given the 
role that quality-of-life was found to play on the resultant ICER through probabilistic 
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sensitivity analysis, the use of the same health utility values for both treatments may have 
led to an over/underestimation of the final effectiveness value and therefore affected the 
final ICERs. Further research should be done to find definitive health utility values for 
patients receiving bevacizumab or cetuximab along with FOLFIRI in the first-line 
treatment to facilitate a more accurate approximation of the ICER.  
Secondly, given a restriction of the information provided in the ECOG3200 RCT90 we 
were unable to use parametric methods to fit a weibull distribution to the PFS curves for 
patients receiving second line treatment consisting of either FOLFOX or combination 
FOLFOX and bevacizumab. Due to this patient PFS outside of the course of the clinical 
trial was extrapolated using the average of the last four months of the trial data. We do 
not expect this to have a significant impact on the results of the model as in the clinical 
trials the majority of patients had progressed by the end of the trial window. 
 From the patient-level data I was able to determine an estimate of PFS for patients 
receiving second-line FOLFOX, however we did not have patient-level data for patients 
receiving second-line FOLFOX plus bevacizumab. When the PFS data found from the 
patient-level data and from the clinical trials were compared it was found that the PFS 
from the patient-level data was greater than that found in the clinical trials. Given that the 
ECOG3200 clinical had found that treatment with FOLFOX and bevacizumab was more 
effective than treatment with FOLFOX alone and given the treatment course of patients 
receiving each possible first-line combination treatment it was not plausible to use the 
patient-level second line data in the bevacizumab plus FOLFIRI model and the clinical 
trial data for the cetuximab plus FOLFIRI and panitumumab plus FOLFIRI arms as this 
would bias the final cost and effectiveness. 
Thirdly, only an approximate cost was used in this analysis for fluorouracil and 
leucovorin which are used in the FOLFIRI and FOLFOX regimens due to confidentiality 
in pricing issues. Due to the fact that these two drugs were used in each treatment option 
we do not expect this to have any effect on the final results. 
Finally, the cost estimates for patients in the best-supportive care state may not fully 
capture the costs of providing treatment as there may be some aspects of  providing best-
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supportive care that may not have been fully captured in the patient-level data. Given that 
the cost values used for the BSC state were constant in all three treatment strategies we 
do not expect this to have an effect on the final ICER values. 
5.4 Strengths 
To our knowledge this is the first project to examine the cost-effectiveness of the use of 
panitumumab and FOLFIRI in first-line treatment for patients with metastatic colorectal 
cancer, as well as the first study to investigate the use of cetuximab plus FOLRIRI and 
panitumumab plus FOLFIRI treatment options in first-line use for patients with MCRC in 
the province of Ontario. 
 Our study was able to conduct OS and PFS survival analyses using patient-level data of 
individuals who received first-line bevacizumab plus FOLFIRI in the province of 
Ontario. Using information on treatment line and the date each treatment was received, a 
PFS curve was able to be constructed from which monthly transition probabilities were 
eventually derived. The use of the NDFP database, along with the OHIP, HCD, CIHI-
DAD, NACRS, and ODB databases also allowed for the determination of monthly state-
dependent healthcare utilization costs. This allowed for a more representative portrayal of 
the costs incurred by the health care payer in Ontario for patients diagnosed with MCRC 
from first-line treatment until death. This analysis may play an important role in helping 
inform health care decision makers on future discussions as to whether to expand the 
number of options for first-line treatment of MCRC by adding cetuximab plus FOLFIRI 
or panitumumab plus FOLFIRI to their provincial formularies. This analysis may also 
give an ideal on potential budget impact.   
6 Conclusion 
We conducted a cost-effectiveness analysis examining both cetuximab plus FOLFIRI, 
and panitumumab plus FOLFIRI compared to bevacizumab plus FOLFIRI using patient-
level data from administrative databases in the province of Ontario as well as relevant 
published data from randomized clinical trials. In the base case scenario treatment with 
bevacizumab and FOLFIRI was found to dominate both other treatment options. The 
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ICER value for cetuximab and FOLFIRI was very sensitive and fell well below the 
$100,000/QALY threshold when the  utility value of first line cetuximab plus FOLFIRI 
increased by 10% or the utility of bevacizumab plus FOLFIRI decreased by 10%. The 
utility of patients receiving these treatments in first-line therapy should be further 
investigated to improve the estimate of cost-effectiveness. This economic evaluation will 
help guide decision makers with reimbursement and policy decisions in light of the 
available information. 
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8 Appendices 
Appendix A: Economic Evaluation in Healthcare  
A.1     What is an Economic Evaluation? 
The use of economic evaluation in health care sector was initially introduced in the 
1960’s and has increasingly become an important tool for health care decision makers 
over time, being applied to both medical technologies as well as pharmaceutical agents.  
The aim of economic evaluations in health care settings is to identify and reallocate 
resources to those health care interventions and programs that offer the greatest health 
returns from money allocated within a limited healthcare budget 115. This is achieved as 
economic evaluations provide information of the relative value for money offered by 
competing treatments either among or between different treatment classes, comparing 
both the costs incurred and final consequences of alternative interventions 115, 116. Since 
the 1990’s cost-effectiveness analyses have been required for an intervention to be 
eligible for reimbursement under public sector drug plans in the province of Ontario 115, 
117
. 
 Unlike other markets, the health care market has an irregular market structure as supply 
and demand are not brought together in a market through price mechanisms, but instead 
health care resources are delivered and/or financed, to varying degrees, by governments 
115
.  Economic evaluation becomes critical in this situation as these governments have a 
limited pool of scarce resources which they must allocate to health care without having 
marketplace signals of what consumers value. This being the case, governments must aim 
to efficiently allocate their health care resources among various competing demands 115.  
Central to economic evaluations is an understanding of the concept of opportunity cost. 
Opportunity cost measures the value of competing options when budgets are finite and 
when investment in one program/intervention will be at the expense of a loss of 
opportunity in another program/intervention 115. Economic evaluation is used as it offers 
a framework for identifying, measuring, and valuing the resource inputs of a health care 
program and the health benefit outputs associated with the intervention 118. 
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A.1.1     Components of an Economic Evaluation 
There are four key components of an economic evaluation. Firstly, a research question 
relevant to the end decision maker(s) must be formulated 117. This research question must 
clearly define the population of interest (eg. specific genotype, tumor etc), provide a 
complete description of all the alternatives which are being compared,and state the 
perspective in which the evaluation will be carried out in 117. 
The second step to performing an economic evaluation is to assess the cost and 
consequences of each alternative 117, 118. Key to determining these costs and consequences 
is the perspective in which the analysis is undertaken. The perspective in which an 
economic evaluation is carried out can range from narrow, for example that of an 
individual hospital, to wide such as the full societal view. In practice four different 
perspectives are commonly used when undertaking an economic analysis; the society, the 
patient, the provider, and the payer 118. The differences in each of the perspectives in 
which an analysis is undertaken can greatly influence the final analysis as different costs 
and consequences can be included or excluded depending on the viewpoint of the 
analysis 106, 107, 108,109, 110,111, 112, 113, 114,115, 116, 118. More narrow perspectives may only focus 
on direct costs and benefits i.e. those costs and benefits directly attributed to providing 
the intervention/program, while more broad perspectives will take into account the 
indirect costs (ex. Productivity losses, lost wages) and intangible costs (ex. Pain and 
suffering) and benefits associated with a program/ intervention 118.  
The third step in an economic evaluation is to carry out the actual analysis. The main 
types of economic evaluation used in health care settings; cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA), and cost-benefit analysis (CBA), cost comparison 
analysis, cost-consequence analysis, and cost-minimization analysis (CMA). The method 
for the identification of costs and their measurement into monetary units for each of the 
four methods is similar, however where each approach is differentiated in terms of how 
they quantify and value the consequences of the interventions 115, 117, 118. The selection of 
what type of analysis to undertake is determined by the research question, the 
condition/disease of interest, and the availability of outcome data 117, 118. 
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The final stage of the analysis is to address any variability and uncertainty of the results. 
This is achieved through the use of either deterministic or probabilistic sensitivity 
analyses which aim to verify the robustness of the initial results and to adjust for any 
variability or uncertainty surrounding the parameters used in the analysis such as health 
outcomes, cost, resource utilization, or probabilities 117, 118. 
Once the analysis is complete it is then open to the interpretation of policy-makers who 
use these analyses as a tool to determine whether certain health interventions or programs 
should be funded or not.  Economic evaluations are a valuable tool for use by decision 
and policy makers in a number of scenarios. Economic evaluations are used by payers 
such as insurance companies or governments to make coverage decisions, using these 
analyses in the context with their inherent budget constraints to ensure that they can 
provide access to pharmaceuticals and other healthcare services 119. Economic 
evaluations can also be used by health care providers, especially in regards to making 
formulary decisions 119. In this context the decision maker would use the results of the 
economic evaluation and along with efficacy and safety information to determine 
whether a particular drug or intervention should represents appropriate cost for value and 
therefore whether it should be funded or not. Economic analyses can also be used by also 
by those involved in selecting healthcare performance measures and developing treatment 
guidelines 119. 
A.2     Types of Economic Evaluations 
In this section I will examine the different type of economic evaluations which can be 
undertaken. 
A.2.1   Cost-Effectiveness Analysis 
Cost-effectiveness analysis (CEA) is a method of economic evaluation which compares 
both the cost and effect of different interventions, and is the most common type of 
economic evaluation undertaken when comparing pharmaceuticals or programs in the 
health care sector 116, 120. The use of CEA is most useful to decision makers who are 
operating with a limited budget and who can only consider a limited number of options 
within a given field.  The use of cost-effectiveness analysis is dependent upon the 
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measure of effectiveness selected for the chosen outcome for which the alternative 
programs/interventions will be compared.  Ideally a CEA should use an effectiveness 
measure which is related to final outcomes such as  life-year gained, however this may 
not be feasible given the information on which the analysis is formulated 118. In some 
cases intermediate effectiveness measures such as number of cases detected, episode-free 
days, or some clinical measure may be used. 
Two different cost-effectiveness ratios are important outcomes in economic evaluations.  
Both consist of a ratio of the costs to the effectiveness of a medical intervention where 
the numerator is the cost of the intervention in monetary units and the denominator is 
expressed in some measure of effectiveness in its appropriate health units 120.  
The average cost-effectiveness ratio is determined for an intervention by dividing the cost 
of the intervention by a measure of its effectiveness. Average cost-effectiveness ratios 
can be determined for various interventions and along with the use of an acceptability 
threshold value can be used by decision makers to assign priorities for resource allocation 
120
. In Canada $75 000- $100,000 per life year saved is used as a widely used as the 
acceptable threshold value for cancer treatments 117. Interventions which are above this 
threshold are considered  to not be of value for money or “bad buys” and should not be 
implemented, while those which  fall below this threshold are considered good value for 
money and should be implemented 120. 
Ideally an economic evaluation should compare the costs and consequences of competing 
alternatives. Average cost-effectiveness ratios fail to consider the competing 
interventions which could possibly be used for the treatment of the same medical 
problem and this lack of comparison represents a weakness in the use of the average cost-
effectiveness ratio in economic evaluations. To address this issue the Incremental Cost-
Effectiveness Ratio (ICER) was designed.  
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Figure 8.1: The Incremental Cost-Effectiveness Ratio 
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The ICER examines the differences in cost divided by the differences in the effectiveness 
of two competing alternatives, given that the measure of effect of the two alternatives 
being compared is the same. The resultant ICER represents the cost per unit of health 
benefit gained from switching from one alternative to another, and represents a more 
informative tool in the decision making process for heath care decision makers than the 
average C/E ratio 120. 
Cost Effectiveness ratio’s can be expressed graphically with the use of a four quadrant 
diagram called the cost-effectiveness plane (Figure 8.2).  The horizontal axis of the cost-
effectiveness plane represents the difference in effectiveness, while the vertical axis 
represents the difference in cost of the treatment options being compared 118, 120. 
Figure 8.2: The Cost-Effectiveness Plane 
 
A health care intervention of interest can be expressed as a point in one of the four 
quadrants when it is being compared to an alternate health care intervention. The more 
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costly an intervention is, the higher its point will be on the vertical axis, while the more 
effective the intervention the more rightward its point will fall. If a point falls in the 
south-east quadrant the intervention is said to be “dominant” in that it is more effective 
and less costly than its alternative, while if it lands in the north-west quadrant the 
intervention is more costly and less effective than its alternative and is said to be 
“dominated”. The use of a willingness-to-pay cost-effectiveness ratio comes into play 
when points land in the north-east and south-west quadrants. Points landing in the north-
east quadrant the intervention are more effective and more costly than its alternative, 
while points landing in the south-west represent interventions which are less effective and 
less costly.  On the cost-effectiveness plane the willingness-to-pay threshold may be 
represented with the use of a line whose slope reflects the amount that the payer is willing 
to pay for a one unit health gain. Points which lay above this line exceed the willingness-
to-pay threshold and therefore may not represent good value for money, while points 
which lie underneath it are below the threshold value and may be worthwhile 
implementing. 
A.2.2   Cost-Utility Analysis 
Cost-Utility analysis (CUA) is based upon the same principle as CEA, however it focuses 
on the quality of the health outcome produced or forgone by the programs/interventions 
of interest 118. In CUA the incremental cost of a program is found in the same manner as 
in CEA, however it differs from CEA in that in CUA the health improvement of a 
program is quantified in terms of some measure of health-related preferences, often using 
quality-adjusted life-years (QALYS). QALY’s are determined through the use of multi-
attribute utility instruments such as the Euroqol (EQ-5D), Health Utility Index (HUI), 
Quality of Well-Being (QWB), or Short Form 6D (SF-6D) 117, 118. An advantage of the 
use of cost-utility analyses is that the use of the QALY provides a standard measure of 
effectiveness, allowing for the comparison of a broad scale of interventions which may 
have different primary effectiveness measures, allowing for the allocation of resources 
based upon the maximization of health gains 117, 118. The use of the QALY as standard 
effectiveness measure also allows for the comparison of different programs/interventions 
where multiple effectiveness measures may be of interest, as well as allows for the 
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incorporation of changes to both the quantity and the quality of life gained or lost through 
the implementation of an intervention/program to be quantified in a single measure 116-118. 
Cost- utility analyses are primarily used when the health-related quality of life is the most 
important outcome of a program, when a number of different outcomes are of interest, or 
when the implementation of a program can affect both morbidity and mortality. 
A.2.3 Cost-Benefit Analysis 
Cost-benefit analysis (CBA) is a form of economic evaluation where the consequences of 
a program are valued in monetary terms, allowing for the direct comparison of the 
“program’s incremental cost with incremental consequences in commensurate units of 
measurements, be they dollars, pounds, or yen” 118. The goal of CBA is to determine 
whether a program’s benefits exceed its costs 116-118. Programs which show a positive net 
social benefit by having benefits exceeding its costs will represent a program whose 
implementation will be worthwhile.  One advantage of the use of CBA is that is has a 
broader scope than CEA and CUA and can be used when comparing health care program 
to  programs outside of the health care sector 117, 118. However the use of cost-benefit 
analysis in health care settings is complicated by the need to value intangible health 
outcomes into monetary values. These monetary values are determined primarily through 
the use of three different approaches;  (1) the human capital approach which places 
monetary weights on healthy time using market wage rates and the value of the program 
is assessed in terms of its present value and future earnings, (2) Revealed preferences 
which examines the health risks associated with a hazardous job and the wage rates that 
individuals would require to accept that job, and (3) with the use of stated preferences of 
willingness to pay 118. A number of methodological issues have been raised with the use 
of these three approaches to value non-monetary health outcomes and thus has limited the 
use of CBA in health care economic evaluations 116. 
A.C     Decision Analytic Modeling 
Decision analytic models are used to find detailed estimates of both the cost and 
consequences of interventions using data from a number of sources including clinical 
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trials, observational trials, public health statistics, insurance databases etc 119. The use of 
decision analytic modeling in economic evaluations for health care 
programs/interventions involves the use of mathematical techniques to integrate clinical 
and economic outcomes, providing a framework for health care decision-making under 
conditions of uncertainty 118, 119.  
The development of a decision analytic model involves four stages. First the decision 
problem must be defined.  This involves defining the recipient group, and the options 
which are to be compared in the model. Secondly, the boundaries of the model must be 
defined. This involves the deciding upon an appropriate time horizon, the choice of 
perspective, and the selection of appropriate measures of cost and effectiveness 118. Once 
the problem and boundaries are defined, the structure of the model must be determined. 
The structure of the decision analytic model is based on decisions regarding how model 
parameters are related and deciding how to characterize the clinical event(s) of interest. 
When structuring the model an analyst must take into account the occurrence of events 
(occurs once or multiple times), whether the probabilities of an event occurring is 
constant or changes over time, how to extrapolate data which may only represent a short 
period of time in to the future, and how to incorporate all the appropriate costs and effects 
117, 118
. 
A.3.1 Types of Decision Analytic Models 
There are three main types of decision analytic models; (1) Decision Tree (2) Markov 
Model, and (3) Microsimulation Models. 
A.3.2   Decision Trees 
Decision trees are the most commonly used structure for decision models in economic 
evaluation. A decision tree is a graphical analytic model, ordered left to right composed 
of different branches, each of which represent different events and their possible 
outcomes 117, 118. Within the decision tree different events are represented by different 
shapes called “nodes”. There are three types of nodes: 
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Decision Nodes         : decision nodes represent a decision which is being addressed in 
the model. Decision nodes are represented in a decision tree with the use of a square box 
118
. 
Chance Nodes          : Chance nodes are used to represent the range of possible, mutually 
exclusive outcomes which can occur after a decision has been made. Each branch coming 
out from a chance node represents a possible outcome, the sum of each of the branches 
starting at chance outcomes must equal 1.0 118. Chance nodes are represented in the 
decision tree with the use of a circle. 
Terminal Nodes         : Terminal nodes represent the endpoint of each possible pathway, 
and are also referred to as the path payoff and can be measured in terms of cost or 
effectiveness ($, life-year, QALY, etc) 118.  Terminal nodes are represented in the 
decision tree with the use of a triangle. 
A.3.3   Markov Models 
Markov models are a type of decision analytical modeling which is used to represent 
random processes which evolve over time and where individuals have an ongoing risk 
over that period of time such as in chronic or progressive diseases 121, 122. An attractive 
feature of Markov models for their use in economic evaluation of health care 
programs/interventions is that estimates of both cost and health care outcome can be 
attached to various Markov states, and with the use of various transition probabilities, 
long term cost and outcomes associated with a particular disease or intervention can be 
determined 121. 
In Markov models, the disease is defined in a number of discrete states which are chosen 
based on clinically or economically important events which occur in the disease process 
121
 . A specific set of rewards can be attributed to each state such as a specific utility, 
cost, or outcome associated with being in that state for every cycle 118.  Markov states 
must be mutually exclusive in that a patient can not be in more than one Markov state at 
any one time 121, 122.  
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In each Markov model the desired time horizon is divided into equal increments of time 
(month, years, day etc) called Markov cycles.  Within each Markov cycle patients can 
transition between the unique Markov states except for one state which is known as the 
absorbing state, the state from which it is impossible to leave. In most Markov models the 
absorbing state is death.  In situations where an event that only has short-term effects 
occurs, it is possible to make use of temporary states 121, 122. Temporary states are defined 
by only having transitions to other states and not to themselves which ensures that a 
patient can only stay in that state for one cycle 122. In certain situations where the 
temporary adjustment from the addition of a temporary state is desired for more than one 
cycle tunnels can be used. A tunnel consists of a number of temporary states arranged so 
that each temporary state transitions to the next in a fixed sequence. A specific health 
utility and cost can be attributed to each specific Markov state 121, 122. The movement of a 
patient through the Markov states within each Markov cycle is determined with the use of 
transition probabilities. Transition probabilities define the speed at which patients move 
through the different Markov states, and for a Markov model with k states, the number of 
all possible transitions between the states are given by a k x k transition matrix 115 . A 
number of assumptions are made with the use of transition probabilities, firstly it is 
assumed that patients with progressive disease do not recover from their disease after 
they move to a progressive stage thus eliminating any transitions from more advanced to 
less advanced disease stages115, 118. 
The second assumption made is often called the Markovian Assumption, and is also 
called the memory-less feature of Markov models. The Markovian assumption states that 
the probability of a patient moving out of a state is independent of the states which they 
may have previously experienced before entering their current state i.e. it has no memory 
of earlier cycles 115, 117, 118. 
A weight of 1 is assigned to every Markov state in which the patient is alive, and a 
weight of 0 is given to the dead state, and after running the model for a large number of 
cycles an estimate of the patients expected life expectancy can be found 118. When the 
outcome of interest is quality adjusted life years, the weight of each state is multiplied by 
the state specific utility to give a final outcome of quality adjusted life years. 
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A.3.4   Microsimulation Models 
Microsimulation models make use of the Monte-Carlo simulation technique which 
generates individual patient histories by applying a set of transition probabilities to 
individual patients. This results in the ability to track changes in that patient’s state, 
resulting in changes in their overall costs and benefits over time 115. In microsimulation 
models individuals randomly walk through the model generating individual outcomes. 
This process is carried out numerous times resulting in an aggregate result for the 
expected value for each patient. Due to the fact that a microsimulation generates 
outcomes for individual patients microsimulation models can be used to track outcomes 
to individual patient characteristics. This tracking of individual characteristics cannot be 
done through the use of Markov modeling, as Markov models use transition probabilities 
on a homogenous cohort 115. 
Appendix B: Model Parameters 
B.1     Monthly Costs 
Table 9.1:Monthly State- Specific Costs Determined from Patient-Level Data and 
Linear Regression. 
First-Line 
Month Total Cost - Patient Level Total Cost - Linear Regression 
1 3,520.17 3,053.77 
2 2,676.71 2,942.34 
3 2,742.86 2,830.91 
4 2,738.33 2,719.48 
5 3,112.64 2,608.05 
6 2,301.70 2,496.62 
7 2,009.13 2,385.19 
8 1,777.57 2,273.76 
9 1,844.78 2,162.33 
10 1,635.25 2,050.90 
11 1,907.94 1,939.47 
12 1,389.65 1,828.04 
13 1,465.26 1,716.61 
14 1,837.70 1,605.18 
15 1,031.59 1,493.75 
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16 1,010.89 1,382.32 
17 1,325.96 1,270.89 
18 853.21 1,159.46 
19 1,381.26 1,048.03 
20 579.04 936.60 
21 642.95 825.17 
22 539.19 713.74 
23 618.15 602.31 
24 918.65 490.88 
   
Second-Line 
Month Total Cost - Patient Level Total Cost - Linear Regression 
1 3,191.43 2,944.30 
2 2,527.02 2,817.30 
3 2,653.80 2,690.30 
4 2,402.88 2,563.30 
5 2,703.16 2,436.30 
Month Total Cost - Patient Level Total Cost - Linear Regression 
6 2,214.06 2,309.30 
7 1,758.58 2,182.30 
8 2,253.72 2,055.30 
9 1,971.27 1,928.30 
10 1,761.97 1,801.30 
11 1,543.22 1,674.30 
12 2,096.02 1,547.30 
13 1,009.04 1,420.30 
14 1,408.79 1,293.30 
15 1,398.88 1,166.30 
16 1,155.43 1,039.30 
17 1,220.80 912.30 
18 868.60 785.30 
19 508.82 658.30 
20 328.41 531.30 
21 363.01 404.30 
22 186.08 277.30 
23 63.85 150.30 
24 20.66 23.30 
   
Third-Line 
Month Total Cost - Patient Level Total Cost - Linear Regression 
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1 3,780.82 3,297.03 
2 3,209.99 3,069.26 
3 3,122.11 2,841.49 
4 2,812.68 2,613.72 
5 1,622.53 2,385.95 
6 2,280.53 2,158.18 
7 1,989.14 1,930.41 
8 1,271.74 1,702.64 
9 1,245.74 1,474.87 
10 1,141.05 1,247.10 
11 537.87 1,019.33 
12 297.59 791.56 
13 1,078.87 563.79 
14 411.76 336.02 
15 236.33 108.25 
16 0.00 0.00 
17 32.57 0.00 
   
Best Supportive Care 
Month Total Cost - Patient Level Total Cost - Linear Regression 
1 3,016.60 2,581.71 
2 1,898.75 2,235.82 
3 1,817.73 1,889.93 
4 1,288.39 1,544.04 
5 1,079.83 1,198.15 
6 1,220.67 852.26 
7 486.35 506.37 
8 1,542.44 1,149.18 
9 344.44 1,021.59 
10 532.18 894.00 
11 1,489.36 766.41 
12 846.32 638.82 
13 401.77 511.23 
14 208.69 383.64 
15 276.11 203.32 
16 125.48 176.72 
17 154.13 150.12 
18 69.33 123.52 
19 113.55 96.92 
20 15.67 70.32 
21 96.89 43.72 
22 30.33 17.12 
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Table 9.2: Monthly Costs Determined from Patient-Level Data 
First-Line 
Month Clinic Home Care Hospital ODB OHIP 
1 $1,761.73 $309.65 $819.83 $347.78 $281.18 
2 $1,150.20 $252.36 $657.65 $332.07 $284.43 
3 $1,048.44 $252.49 $708.70 $394.71 $338.52 
4 $1,041.93 $252.04 $693.30 $413.10 $337.96 
5 $882.20 $250.02 $1,199.33 $359.95 $421.14 
6 $772.02 $217.98 $586.05 $341.55 $384.10 
7 $705.48 $205.58 $487.79 $319.09 $291.19 
8 $551.50 $173.10 $468.60 $246.30 $338.07 
9 $473.03 $164.49 $696.33 $222.65 $288.28 
10 $377.34 $148.57 $534.29 $291.07 $283.98 
11 $449.80 $136.61 $812.25 $249.06 $260.22 
Month Clinic Home Care Hospital ODB OHIP 
12 $316.20 $120.95 $449.88 $239.19 $263.43 
13 $307.09 $122.80 $615.59 $163.94 $255.84 
14 $310.46 $96.97 $976.63 $195.95 $257.69 
15 $379.22 $100.75 $42.07 $313.35 $196.20 
16 $269.55 $78.42 $294.64 $161.73 $206.55 
17 $233.75 $68.12 $569.23 $203.13 $251.73 
18 $276.97 $56.71 $178.46 $141.10 $199.97 
19 $195.85 $49.70 $666.25 $127.11 $342.35 
20 $132.35 $52.10 $91.69 $125.41 $177.49 
21 $96.61 $35.63 $154.68 $118.02 $238.01 
22 $87.42 $34.65 $104.68 $88.43 $224.01 
23 $76.73 $24.30 $239.62 $80.47 $197.03 
24 $83.87 $23.20 $516.52 $121.37 $173.69 
Second-Line 
Month Clinic Home Care Hospital ODB OHIP 
1 $1,764.80 $309.28 $407.65 $470.78 $238.92 
2 $1,043.90 $271.26 $502.82 $416.66 $292.38 
3 $1,017.70 $251.33 $640.48 $416.50 $327.79 
4 $906.23 $246.25 $554.29 $378.84 $317.27 
5 $830.32 $229.88 $935.36 $361.84 $345.76 
6 $722.96 $222.58 $610.91 $328.48 $329.13 
7 $759.41 $206.74 $202.51 $310.03 $279.89 
8 $564.06 $244.91 $901.69 $308.91 $234.15 
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9 $453.94 $217.75 $655.85 $248.23 $395.5 
10 $531.91 $191.06 $490.97 $269.06 $278.97 
11 $450.74 $174.29 $436.79 $259.01 $222.39 
12 $435.40 $115.80 $1,128.98 $176.02 $239.82 
13 $383.33 $87.96 $153.01 $193.99 $190.75 
14 $396.74 $107.45 $426.88 $223.41 $254.31 
15 $325.79 $113.17 $570.80 $194.14 $194.98 
16 $277.54 $87.68 $316.23 $219.67 $254.31 
17 $323.46 $75.55 $470.96 $152.85 $197.98 
18 $304.14 $124.84 $0.00 $235.79 $203.83 
19 $115.32 $22.70 $0.00 $121.18 $249.62 
20 $0.00 $14.43 $0.00 $93.02 $220.96 
21 $0.00 $46.18 $0.00 $40.48 $276.35 
22 $0.00 $59.83 $0.00 $29.02 $97.23 
23 $0.00 $0.00 $0.00 $0.00 $63.85 
24 $0.00 $0.00 $0.00 $0.00 $20.66 
      
Third Line 
Month Clinic Home Care Hospital ODB OHIP 
1 $1,504.60 $278.44 $1,285.40 $279.42 $424.56 
2 $1,001.50 $331.06 $988.85 $324.69 $584.61 
3 $771.07 $358.23 $4,905.00 $309.04 $504.37 
4 $881.47 $270.64 $1,005.50 $351.89 $328.82 
5 $938.37 $210.73 $0.00 $172.38 $301.05 
6 $467.58 $0.00 $0.00 $144.58 $306.27 
7 $520.24 $334.46 $814.02 $135.42 $202.06 
8 $450.76 $172.13 $280.57 $151.02 $223.14 
9 $643.34 $120.00 $0.00 $54.07 $428.33 
10 $322.99 $349.51 $0.00 $289.03 $179.52 
11 $0.00 $184.51 $0.00 $267.49 $85.87 
12 $0.00 $127.63 $0.00 $51.81 $118.15 
13 $0.00 $0.00 $0.00 $602.38 $476.49 
14 $0.00 $0.00 $0.00 $0.00 $411.76 
15 $0.00 $0.00 $0.00 $0.00 $236.33 
16 $0.00 $0.00 $0.00 $0.00 $0.00 
17 $0.00 $0.00 $0.00 $0.00 $32.57 
Best Supportive Care 
Month Clinic Home Care Hospital ODB OHIP 
1 $100.44 $316.49 $1,363.11 $296.78 $939.78 
2 $54.60 $256.08 $681.57 $352.03 $554.47 
3 $62.54 $166.78 $839.50 $276.85 $472.06 
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4 $81.84 $155.25 $522.53 $235.11 $293.66 
5 $42.14 $138.01 $548.35 $159.62 $191.71 
6 $5.93 $123.03 $733.82 $159.37 $198.52 
7 $4.12 $54.80 $192.60 $84.81 $150.02 
8 $0.00 $102.41 $1,108.60 $116.89 $214.54 
9 $2.99 $95.58 $0.00 $100.85 $145.02 
10 $0.00 $70.40 $0.00 $38.69 $423.09 
11 $0.00 $114.27 $1,214.93 $55.83 $104.33 
12 $0.00 $134.84 $493.44 $57.33 $160.71 
13 $0.00 $80.84 $218.67 $40.60 $61.66 
14 $0.00 $52.30 $77.58 $27.78 $51.03 
15 $8.26 $27.99 $124.09 $34.81 $80.96 
16 $0.00 $23.22 $0.00 $35.77 $66.49 
17 $0.00 $9.54 $0.00 $76.64 $67.95 
18 $0.00 $0.00 $0.00 $42.42 $26.91 
19 $0.00 $0.00 $0.00 $41.58 $71.97 
20 $0.00 $0.00 $0.00 $1.79 $13.88 
21 $0.00 $0.00 $0.00 $73.96 $22.93 
22 $0.00 $0.00 $0.00 $0.00 $30.33 
 
B.2     Transition Probabilities 
 Table 9.3: Monthly Transition Probabilities 
Month 
 Beva + 
FOLFIRI 
 Cetux + 
FOLFIRI 
 Panit + 
FOLFIRI FOLFOX 
FOLFOX 
+ Beva TL Panit BSC 
1 0.0317 0.0113 0.0141 0.0513 0.0461 0.0116 0.0418 
2 0.0436 0.0228 0.026 0.0513 0.0461 0.0195 0.0636 
3 0.0496 0.0309 0.0338 0.0513 0.0461 0.0242 0.0755 
4 0.0539 0.0377 0.0401 0.1181 0.0801 0.0279 0.0844 
5 0.0573 0.0436 0.0455 0.1181 0.0801 0.0311 0.0917 
6 0.0603 0.049 0.0504 0.2441 0.0955 0.0338 0.098 
7 0.0628 0.0541 0.0548 0.2441 0.0955 0.0362 0.1035 
8 0.065 0.0587 0.0588 0.2094 0.1455 0.0385 0.1084 
9 0.067 0.0631 0.0626 0.2094 0.1455 0.0405 0.1129 
10 0.0689 0.0673 0.0662 0.2929 0.2339 0.0424 0.117 
11 0.0706 0.0713 0.0696 0.2929 0.2339 0.0442 0.1208 
12 0.0722 0.0751 0.0728 0.2254 0.1611 0.0459 0.1244 
13 0.0737 0.0788 0.0759 0.2254 0.1611 0.0475 0.1278 
14 0.0751 0.0824 0.0788 0.1835 0.2053 0.0491 0.131 
15 0.0764 0.0858 0.0817 0.1835 0.2053 0.0506 0.134 
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16 0.0776 0.0891 0.0844 0.1835 0.2404 0.052 0.1369 
17 0.0788 0.0923 0.087 0.1835 0.2404 0.0534 0.1397 
18 0.0799 0.0955 0.0896 0.2929 0.1181 0.0547 0.1423 
19 0.081 0.0985 0.0921 0.2929 0.1181 0.0559 0.1448 
20 0.0821 0.1015 0.0945 0.2929 0.0742 0.0572 0.1473 
21 0.0831 0.1044 0.0968 0.2929 0.0742 0.0583 0.1496 
22 0.084 0.1072 0.0991 0.1544 0.2929 0.0595 0.1519 
23 0.0849 0.11 0.1013 
 
0.2929 0.0606 0.1541 
24 0.0859 0.1127 0.1035 
 
0.1453 0.0617 0.1563 
25 0.0867 0.1154 0.1056 
  
0.0628 0.1583 
26 0.0876 0.118 0.1077 
  
0.0638 0.1603 
27 0.0883 0.1205 0.1097 
  
0.0648 0.1621 
28 0.0892 0.1231 0.1117 
  
0.0659 0.1643 
29 0.09 0.1256 0.1138 
  
0.0668 0.1657 
30 0.0907 0.128 0.1156 
  
0.0678   
31 0.0915 0.1304 0.1175 
  
0.0687   
32 0.0921 0.1329 0.1194 
  
0.0696   
Month 
 Beva + 
FOLFIRI 
 Cetux + 
FOLFIRI 
 Panit + 
FOLFIRI FOLFOX 
FOLFOX 
+ Beva TL Panit BSC 
33 0.0928 0.135 0.1211 
  
0.0705   
34 0.0936 0.1373 0.1229 
  
0.0714   
35 0.0941 0.1398 0.1248 
  
0.0723   
36 0.0948 0.1419 0.1264 
  
0.0731   
37 0.0955 0.144 0.1282 
  
0.0739   
38 0.096 0.1462 0.1296 
  
0.0747   
39 0.0967 0.1482 0.1315 
  
0.0756   
40 0.0975 0.1505 0.1333 
  
0.0763   
41 0.0979 0.1527 0.1347 
  
0.0772   
42 0.0983 0.1541 0.1361 
  
0.0779   
43 0.0992 0.1565 0.1379 
  
0.0786   
44 0.0996 0.1592 0.1393 
  
0.0795   
45 0.1002 
 
0.141 
   
  
46 0.1006 
 
0.1418 
   
  
47 0.1014 
     
  
48 0.1018 
     
  
49 0.1022 
     
  
50 0.1029 
     
  
51 0.1032 
     
  
52 0.1032 
     
  
53 0.1046             
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Table 9.4: Fixed monthly transitions from first-line treatment to cancer free after 
surgery for metastases. 
Model Transition Probability 
Bevacizumab to Cancer Free 0.001536953 
Cetuximab to Cancer Free 0.003423096 
Panitumumab to Cancer Free 0.008284798 
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